Archive of SID

(./-%,) %) "&*+ ) !"&'( % !"#$ 0"#12 34&52

!"#$ %&'(')'*+,

)
6&78&( 6&9:2

%$#!"
-./ 0 12345
32& 3224/5 6284 6.2+ 78&4# # -8<9, 0$&+;< ! -.4/0 3+ "$&1 3& &,%&'( 0#" )*<+2 0&,6$;< ! 3"4&#2
>4 B'2C4 .-8<9, %&'( 0$/4/ /'84 !-'5 ;<&=2 >4 ?-88& &544 4" ;@*<+2 0&,0"&'.+ # &,%.":# -8 4/0;2
"$ ;,&9! # -8&;2 E'& )*<+2 0&,0"&'.+ "$ &,6! 75 D"$ 3+ ?;<&'( 0&,0$&+ ;< ! # &,6$;< ! 75
.-(&+;2 1FG2 # -.@2 ?$"4/2 684 6&2"$ # H.+I0 041+ )*<+2 0&,78&2>! $"/2
3284"4 )2*<+2 M2=82 .L >4 !$&@<2J4 &2+ 4" %&'( 0$/4/ /'84 &+ K=012 ;J&J4 # )*<+2 ;<&=2 1:&< 34&52
:12.P )&2,O/*2J 18&2J &2+ D1<I2 0&,6$;< !/4! :-8(&+;2 $"4/2 684 32&( ;<&'( 0&,6$;< !/4! .-8&' ;2
:12.P )- /2(;22 "/S0 %&'( ;T&S<U4 3& ;8&,6$;< !/4! # (ABH Q<9.J # ;<R&+ 0"&9>&J 0&,6$;< !
6/U O&5< 4 ?;7*2&< ;C 3& &,6$;< ! 684 >4 E8 1, -: 0&,0$&+;< !/4! .(6&9 4 %&'( 0&,6$;< ! Q<9.J
:12.P 6/2U O&25< 4 Y"4/25 # )*<+2 0&,0"&'.+ O#G92 ?- /(;2 $&V84 - /.( >4 W( 0"$& X"/T 3+ #
%22#&52 ?6/U O&5< 4 >4 W( 04"/("/( ?64$4>/ 6/.'84/4! ;8(/<.J/=2#10 ?6/.'84/4! ;8(/<.J/=2#10 Z#"-8J
.-8(&+;2 ?- /.( >4 W( ;8(/<.J/=2#10 # 6/U O&5< 4 O&= $ 3+ ;<&'(
$1+"&& 041+ ?&,78&2>! \8&< 1.9@0 !/[ # ;<&'( 0&,0$&+;< ! # &,6$;< ! ;+&8$" &8 ;+&8>"4 !/[ >4 B'C4
6&22"$ # H.+I0 3+ # %J4 !-88& %84-, ^.[T 6&2> "$ _J&82 "&'.+ "$ ;+&8>"4 _J&82 0&,]#" ^.[T
.-8&' ;2 E'& 3C/+12 0&,0"&'.+ 1<*+
6/U O&5< 4 ?;<&'( 0$&+;< ! ?;<&'( 6$;< ! :%.86" 74*6"

,-/+/)* : '("$!% &$!"#

,-/33/2 : 01$./ &$!"#

3@++2?332> :0)7/ :5;<= ; ,!- 4"%)"$ ./ 01253/ 5 045!86 0:"7 87*68 ; ,!- 4"%)"$ 9"%+%&# '(18 !"$%")*$ ; < !:!"!#$$ PhD :45678 9:68 ;3

!"
www.SID.ir
Archive of SID
EF !"CD B3 A!"#4 B, A!5%
<"2K<H$5 !% 1+T!% NC8 ,"\7a 4!`:!8 s$ I+)`G* ?p
'HJ/ !% 8H ;4"D08 4"+G#5;"$/;+t* 4!\GT/'HJ/ ]D"%)8
.%!$% !$1;b "t:6 <"24!"$1T <"1n <5! B'd$1)*$ 4"d !%
<";1n 8;D ";t:6 4!;"$1T 4"L#$ 8D 1c<8 'HJ/ ,;4 4"e(
';;HJ/ 0U!";;- <";;1n <5! CD62P !!;;Cu 5 ';;HJ/
platelet activation ) PADGEM vJ\;;b CD62P .%!;;40;;8
A;;+8"" (dependent granule-external membrane protein
8;H ;<)72 0$"24!`:!8 5$ <$A%$!""- "2I+)`G* .(j);408
91U";C8 5 :517 i!+G#5;"$ 8D ;+t* <"24!\GT 4"L#$ !%
<5! ";2 I+)`G;* ?E .;;"!$% ';:"-% r! 5$ "2,6 !!\7 5
B";2];+(51#!" <5! ";2I+)`G;* ?L B4"+G#5;;"$ <";24!G*
<5! ";2I+)`G;* ?P 5 ";2];* B 5 ";2]*T B"2'+*!"!8
.;;"!$% %!U5 "2'+*!$!"H"f85 "2'HJ/ B:517 i!+G#5;"$
!% 02";#!H 9;;8 8;D CD62P B';HJ/ ,;4 4"e( 5$ R/
A%1;D ,5!% 8;D RS;* 5 %!408 12"u 'HJ/ <"1n VP*
8;7$"%8 !% .(2)%%1;T0;8 .;$1M# ";2i555';+: !% 5 A;4
5$ 0;;<n <"#;;*J/ 05! 8;;D A;;;4 8;;+C# <";;2';;HJ/
= BC)9!;( 0("D B (Platelet Rich Plasma = PRP)'HJ/
!$;;%8 I$1#x";D 8H ;4 _M18 BR$51(6 5 (Buffy Coat
!$;;%8 I$1)#H 5 PRP 8D y!D18 (CD62P)'+:"e( _-"4
9;G)M8 <";2A"f);*% I+;D 0)d .'*$ R$51(6 8D y!D18
!"`;1D .(+)%!$% %!U5 0$"295"t# 1q" I$$ 5$ '+" R$51(6
!% <1)8!)$";*!G( 05! ";D CD62P 0*!1D !% ,$!"`#2 5
B,$1;C# A";f$"/ !% PRP 05! 8D A;4 8+C# 0)HJ/ A%!561(
!% <!$;;Cf" i!;* 55! !% ,6 !$;;%8 8;H ;;"%!#" 0!$'T
4!;G&8 CD62P 8;H 0:";d !% ';*$ 1)#H "2'HJ/ VP*
%";%e"$ !% K;%" 1;D A5J;7 "2'HJ/ .(>)%!D 8)("$ K$$'($
!% IgG <5";d 0;<#$$ <";2R`GS;#H <5";7H"/ !% B,!-
";2z!";b 5 ";2<1)H";D .;$1M# 5 N:"* %$1($ ,!- 0%1T
<$1;D B0G8";d ,!;a N;2 ';HJ/ {;b$5 !% .;"!$% ':"-%
.$1M# 'CU "2!$!- 8""f+D 8D 0<#$$ <"2R`GS#H ]$!&#
5 "2'+*!`: "D N+%)78 K<H$5 |$1/ 5$ "2'HJ/ .;4"D08
0D";C):$ <"28P*$5 1$"* 5 "2I$"H!#H B"2I$"H!)$"* V41#
|;$1/ 5$ ";2';HJ/ .(*);;"!$% K;%" o"C):$ N+q<# !% '+"
0`+)$!;;"% <"24!G* ,;4 4"e( 8D 1c<8 B CD11b/CD18
[;*!# ";2,6 (R$5!)+;*!T"() ,;;4 A;;+eGD '$"C" !% 5
!#
&'$('
,6 <";2A%!561;( 5 'HJ/ %!!8 !% 0#"+GH 8:"%8 I$$ !%
8;D 0;<#$$ N);7+* !% "2'HJ/ K%" 8D 1L)M8 <$A!"4$ 5
";D 8PD$! !% 0#"7J/$ RS* .%!4 08 O1P8 88;%8 9!!=
";D 1);1+D 0$"<;46 'CU .%%1T08 8$$!$ 'HJ/ < !:!"!#$$
VP;* <";2, 0;)"6 %!!;8 !% 0*"*$ 9"7J/$ B8:!%8 I$$
!% ";2,6 K;%" ,";2, 0;)"6 I;$$ ;;X <%";D0;)"6 ,'HJ/
9$1++Z# 0-1D ,,!- 4"%)"$ Y!$!7 5 9G)M8 <"2<!"#+D
A!;&" ,';HJ/ VP;* 0;<#$$ ];8$!7 "$ 5 'HJ/ "D [\#18
^$";)" 5$ <1;+TA1CD 5 0)HJ/ <%"D0)"6 5 "2, 0)"6 0*!1D
.;"!408 9+=!# "2<!"#+D _+M1# !% "2,6
:&,6! ;*` 75 # &,%`'( ()44
)?@ 1;Pb ";D 8);72 ;;b"( 0`a!H <"24!G* "2'HJ/
";2';HJ/ 0e+\/ %$;e# .;<)72 +?33 fL Ncd 5 ,51`+8
1;;)+:51`+8 1;;2 !% 32----?@2---- ,!;;- 0%1;;T !%
";2'+*!$!"H"f8 5$ ,$!M)*$ 'Z8 !% "24!G* I$$ .;4"D08
0%1;T !% ";2';HJ/ i!;* 5% %5;;d .(3);"!408 ;+:!#
.;$1M# 5 <5";*$;U 4";&/ !% ";2,6 0%D"8 5 A%!D ,!-
A1;+-l 5';U 0;)HJ/ 0;GH A%!;# 5$ %j- %5;d .;"%1T08
4";;&/ 0;;T!'D 8;;D J);;\8 %$1;;($ !% 5 ';;*$ 0:";;&/
4";&/ !% 0;)HJ/ A%!;# ]H 5$ %,- %5;d B(0:"f8!<GS*$)
.';*$ ,!;- %";%e"$ !% "2'HJ/ 0#"+d K%" .());4"D08
.;;"!$% 'H!";18 N;-5 N+81;# 5 8;)M: %"c$$ !% "2'HJ/
8;H A;;4 A;+;4!/ 0H5";" R`+:"H!`+GT "D "2'HJ/ VP*
B%;;;;;e)8 0$";;;;1n <";;;;2I+m#51;;;;/ !;;;;`+GT <5";;;d
o.;U <";2I+m#51;/ 5 "2;;+S+:!`+GT B"2 ;$!"H"*0G/!H!8
'd$1);*$ 4"d !% <"2'HJ/ .(j);4"D08 0$"#*J/ A;4
B,6 <";24!D!#51`+8 5 I+)H$ <"28)4! 5$ <$8`\4 ]+:% 8D
0%1;T !% 0)HJ/ 1#7 [*!)8 .;<)72 ;+p!`7$% ]`4 8D
0$";24!;"$1T ";2';HJ/ !% .';*$ 55! 3- %5;;d B,!-
<";2I+m#51/ :1+q" ;"!$% %!U5 9G)M8 <"2I+m#51/ <5"d
B(vWF);;"$1\G$5 ,!;( ]8"7 B(Adhesion proteins) ,"\7a
0;)HJ/ @ ];8"7 BI$;"!S;*!\851# BI+)`"51;\+( B, !<$1\+(
B0;)HJ/ ;4! ]8"7 B0$$5r! ]8"7 B<%"%e"$ ]8$!7 B(PF4)
.(@)(CD62P)I+)`G* ?p 5 (TGF-!)")D ?!!8!# ;4! ]8"7
www.SID.ir
Archive of SID
,"f$"4 ,"T38
B"81;;* !% A;;;4 <!$;;;Cf" <";;2';;HJ/ BA;;;4 ;;;#c<8
1;Å$ ';&# <"2'HJ/ B'HJ/ 5$ |)18 <"2]`+#!"/51`+8
<";2A%!561;( É$!;"$ 5$ A'+G+(!+: 'HJ/ 5 0$"+#+4!)( %$!8
I+G+(!m# ,!a 0"%5'($ %$!8 5$ A%"t)*$ .(@);<4"D08 0)HJ/
";8$ %!;40;8 0;)HJ/ 1#7 8#+" K$$'($ ñ7"D BI+<+#51/6 5
%1D!";H B8;G8"d ,";"5 5 4";t/$ !% "2,6 1Ñ8 0\""U 9$1Å$
<1;f$% 9x!L&8 .%5"*08 %5;&8 $! "2,6 {+*5 <!"c#
];Ö8 ;"!;40;8 A%"t);*$ ';HJ/ I$'f$";U ,$!;<7 8;D '+"
<"24!\GT B"1n 8D ]L)8 , !<$1\+( <5"d '81b <"24!\GT
A;+;4!/ <"24!7SH51`+8 B RGD <"2;+)S/ 8D ]L)8 '81b
plateled-reduced ) HLA N;H <";2';HJ/ B, !;<$1\+( "D
.(FVIIa)'t2 <%"%e"$ ]8"7 5 (HLA
:;#c<8 <"2'HJ/
.'*$ 0)HJ/ A%!561( 8+C# !% 0:!\b ]D"b 05! B%"#c"$
Dimethyl ) DMSO %+ !% A;;;4 ;;;#c<8 <";;2';;HJ/
4";;* A% ";;# ?*- ºC <";;8% !% ,$!;;#0;;8 $! (Sulfoxide
%1;`G#7 5 ]`;4 BA;4 ;#c<8 <"2'HJ/ .%!#" <!$;Cf"
9!;;b "8$ ;<2%08 '*% 5$ <;d "# A"f1$"856 !% $! %!-
.;<$"#"08 Ütd ,;D !% $! %!- s+#")*!#2
:"81* 5 {$"8 <"24!G&8 !% A;4 <!$;Cf" <"2'HJ/
5 05$%1;;/ I;;( ,,$!";;`#2 5 1);;7+#("2 !";;D I+;;:5$
O1;;P8 $! "81;;* !% <!$;;;Cf" <$1;;D ';;HJ/ <!56];;#7
$! 0T%!;:6 ,"`8$ "81* !% 'HJ/ <!$;Cf" 8a1T .;"%!#"
A%!561;( 8;+C# I+d !% 0T%!:6 8á""<a "8$ B;2%08 K2"H
0T%!;:6 01);7T {"";8 "81;* ,;;4"D A;;4 %";c$$ 0)HJ/
%1;`G#7 5 ";%D %!!;8 !% 0;tG)M8 9$1;q" .(3))%!;40#"
5$ 0;-1D .%!$% %!;U5 "81;* !% A;4 <!$;Cf" <"2'HJ/
<";2';HJ/ <%1;`G#7 ';$'8 1f""+D A;4 9"\Å$ <"2"7%$
A;4 <!$;Cf" <"2'HJ/ 8D '\7" "81* !% A;4 <!$;Cf"
I+;%%&8 0;-1D ";8$ ;<)72 ()- ºC ?)@ ºC):"#$ <"8% !%
O1;P8 $! ,;;D !% !!H.8 <"2'HJ/ %1`G#7 5 "%D K2"H
B"81;* !% A;;4 <!$;;Cf" <";2';HJ/ .(3)?3@);"$A%1H
8G+;;*5 8;;D ,!;;- 0%1;;T 5$ {$1;;* <5";;7H"/ ';;&#
!% GPIb <"2A;"1$./ .;"1+T08 !$1b <;;\H <";2 "(51H"8
!$
'(J/ < !:!"!#$$
!$!;-8;""f+D <";24!G;* K;%" 5 ;"!408 "2!$!- 8""f+D
N;C8 R$551G`;*$51#6 9"e$";X 01)7T !% '*$ I`#8
R`$1#";8 8D 0b517 .+*6 ]&8 !% v"e$1* "2'HJ/ .;4"D
0)("D .+*6 5 5"n6 $! N+81# ;"5! B;<\7a08 0:!G* }!"-
B;4"\" A;4 41)<H 0)HJ/ '+:"e( 1T$ "8$ ;<2%08 K2"H $!
5 s;+#!\851# %";d %$;;7"$ 8D 1c<8 0)HJ/ 5!\851# ;+:!#
];&8 !% 8;)("$ {;#c# <";2';HJ/ .%!;408 ~J/ [7D
8H ;<<H08 %$56 <!b 0$"+#+4 ol"U ]8$!7 B0b517 .+*6
.%!;;40; 8 ,!;;- 0%1;;T !% <";;24!G;;* o.;;U ñ;;7"D
;;4! ];8"7 5 CD40L ,!a 0G8$!7 A;4 4"e( <"2'HJ/
'$";## B";2]* s+)$!;"% ,;4 4"e( 8D 1c<8 8H A%!#" %$56
VP;;* PSGL-1 .;"!;;40;;8 ";;2';;HJ/ ,;;;+eGD 5 ";;2,6
!5;;;%8 $! ';;HJ/ ";;D Ä";;## I+; :5$ B";;2];;* s+)$!;;;"%
.(,);"5"*08
:;<`'( 0&,!$"#!1R B4/ 4 (a
5% 8D (platelet concentrate; PC)NH$1)8 'HJ/ A%!561(
';;*% 8;;D 9!;;H0(";;D 5 ';;HJ/ 5$ 0;<n <"#;;*J/ 05!
;"5! 5 !t$1)""* !5% !% B05! 5% I$$ 95"t# .(j);$608
;+t;* <";24!\GT 5 'HJ/ %$;e# !% 8H ;4"D08 "2,6 8+C#
!% <1f$% 05! R$51(6 .;<H08 1Å$ BA%!561( !% A;""#+b"D
%1;t<8 A;;<<H$;2$ 5$ (R$51;( 'HJ/)0)HJ/ A%!561( 8+C#
8;+C# 0)HJ/ <"2A%!561( <!$;Cf" .*"<8 <"8% .(@)'*$
5 N;$J8 ';H1d ";D )-?)@ ºC !% B PRP 5 BC 0/ A;4
0`+:!D";)8 1;q" 5$ ";8% I$$ !% "2'HJ/ 8H ;4"D08 i5$;8
.(3-);<)72 4"e(
B0;)HJ/ <"2A%!561( 0D"$5!$ <$1D 02"f1$"856 0*!1D
B0)HJ/ <"2A%!561( 8+C# 5!c8 "8$ A;4 5"n6 '*$ "29;8
8;7$"%8 ];D"b .;;4"D0;8 ,;D !% "2,6 <"%D 0*!1D ;<85"+"
<";2';HJ/ "D 0)HJ/ 9x!L&8 ;$;U <"2$;$;""H ,%!D
!% 5!$% 5 $.n A!$%$ 9"8$':$ 5$ BA5"# ]8"H ,!- 5$ A;4 8+C#
4!;L&8 s;$ B5!;c8 '("$!% <$1D 5 '*$ (FDA)"`$186
$! A5";# <";2'HJ/ '("$5"D 5 "%D %++ ]b$;d ;$"D 0)HJ/
.(33);4"D 8)4$%
';HJ/ B(R$51;( ';HJ/)R$51;( 5$ ];="d 'HJ/
';HJ/ B(%!;4 Ç1L8 ;$"D '7"* @ Ç1u 8H)A;4 8)74
www.SID.ir
Archive of SID
EF !"CD B3 A!"#4 B, A!5%
";D ";2, 0;)"6 I;$$ 5$ 0-1D .%!$% %!U5 <%;e)8 0" 0)"6
5 ABH <";2, 0;)"6 ];Ö8 ;<);72 ~1);18 "24!G* 1$"*
0;;;-1D 0;;;:5 B HLA (Human Leukocyte Antigen)
Human Platelet );"!;40;8 o!;7&8 ';HJ/ 0="L)-$
,$!;#0;8 $! 0)HJ/ <"2, 0)"6 .(32 B3+) HPA (Antigen
0tG)M8 É$!"$ 9!!= 8D "2,6 0$"+#+4!+D '+2"8 Ä"*$ 1D
:'(1T 1q" !%
5 ";2I+m#51/!;`+GT <5! :0#$!;;+2!D1H <";2, 0)"6(9:$
. Le B P B (ABH "$) ABO <"2, 0)"6 ]Ö8 "2;+S+:!`+GT
0)(";D <!"T5";* <"2, 0)"6 ]Ö8 :0<+m#51/ <"2, 0)"6(o
1;;;+q" 0$";;;2I+m#51/!;;;`+GT (HLA-A/B/C) I ÄJ;;;H
. GPIb/IX/V B GPIIb/IIIa
];Ö8 ;"%1T08 ]L)8 "2'HJ/ 8D 8H 0$"25!$% :"2I)/"2(}
.I$;+<+H 5 I+<+H BI$!"S2
";2<%";D0;)"6 É$!;"$ Ç;2 ;<"$!#08 "2, 0)"6 I$$ 8#2
8);7D$5 <"2<%"D0)"6 5 "2<%"D0)"6!:6 B"2<%"D0)"6!#$ :1+q"
.(3>);"1+T !$1b ,(0$5!$% <"2<%"D0)"6)5!$% 8D
: ABH <"2, 0)"6
É!;" 5% 1;2 5$ 0\+H1# B0)HJ/ VP* ABH <"2, 0)"6
5';U ";$ 5 ';HJ/ <";1n VP* 8D "#*J/ 5$ A;4 o.U
';HJ/ VP* ABH ,$'+8 .;<4"D08 'HJ/ 0$"1n !")-"*
.(32 B3+)'*$ 95"t)8 1f$% %1( 8D <%1( 5$ 5 1+Z)8 vJ8"H
B";2';HJ/ VP* !% B A51T , 0)"6 ,$'+8 ;*!08 1q" 8D
A51T <"2, 0)"6 %$;e# .;4"D A A51T , 0)"6 ,$'+8 9L"
1;2 <5! 4!;`:!8 3+--?)3-- <1)8!)$"*!G( 05! 8D A
.(3+)'*$ A;4 A%5 I+#M# 'HJ/
: HLA "$ 0)("D <!"T5"* <"2, 0)"6
5 !$%8)72 <"24!G* <5! B HLA- Class I <"2, 0)"6
I$1;#N;C8 0;)HJ/ HLA .;;"!$% %!U5 "2'HJ/ VP* !%
I$$ Nq7$ KMD .;<4"D08 ,;D !% HLA-I <"2, 0)"6 {\<8
8;Gd18 5$ A;""#+b"D 5 'HJ/ <"1n !")-"* 5'U "2, 0)"6
5$ '; +" 0H;;;"$ 1$%";;%8 ";;8$ ;<);;72 0)+; *!$!"H"f8 ];;8"`#
";24!G;* I;$$ <";1n o.;U ";2'HJ/ Ç$1/$ <"#*J/
B';(J/ <5! HLA-I <"24!`:!8 %$;e# .(3- B33);"$A;4
!%
1++Z# ";D 5 ;"!40;8 (Cluster)<;<D8;)*% ,"2';HJ/ VP*
i!;* É!" A;;"1$./) 62!2 <";2A;"1$.;/ 8;D 0;$"Ñ( ]`4
.(j B3j B3@);<\7a08 "2 "(51H"8 <5! (CR3 B,"#GS#H
:0$"+#+4 ]8$!7 "D A;4 !5"c8 <"2'HJ/
1;+n 8;D 1;c<8 BKt<;D à$!5"8 !!" 5 I:$!!7/ 5$ A%"t)*$
!% 8;H 0$"2'HJ/ <$1D "2Ä51$5 5 "2<1)H"D <5"*4"e(
(Vit B2)I$5J(!;\$! .%%1;T08 B;"!408 <!$;Cf" )@ °C
";2, !#";/ <5"*4"e( 1+n !% <%"C<1+/ ]8$!7 1f$% 5$ N2
.;4"D08
:'HJ/ 5$ |)18 <"2]`+#!"/ 51`+8
|);18 <"24!`$5551`+8 {b$5 !% "2]`+#!"/ 51`+8 I$$
4";* ];Ca 5$ K+;D !";D I+:5$ 8H ;<)72 'HJ/ <"1n 5$
<!$;Cf" 0/ 5 %!- 8D %!- ]8$!7 I$$ .;";4 O1P8 K+/
<"#;*J/ NH$1)8 <"2'HJ/ !% 5 ;"!408 %"c$$ "2'HJ/
.;"!408 A;$% !$$1H o!*! 5 A5"# ;#c<8
'HJ/ <%"%e"$ '+:"e( <$!$% 0)HJ/ <"2]`+#!"/51`+8
i!+G#5;;"$ o";* 8;D .;<)72 <%"%e"$ K+/ '+="- 5 ]8"H
K$$';($ $! ";2';HJ/ 4";L#$ 5 ;"!;40;8 ];=5 0b517
8H (Infusible platelet membranes) IPM A%!561( .;<2%08
R<$";*!+D 0"";S#H [;*!# 8);4.T &$!";# <";2'HJ/ 5$
,";1" .;;4"D0;8 -/+ 9m 1Pb 8D '*$ A;4 8+C# B"+"1t+:"H
'7";* + ]b$;;d ';*$ !%";b A%!561( I$$ '*$ A;4 A%$%
0!;T <'$1"!- ,;4 0"x!/ ,"85 B,;D !% |$!'# 5$ ;eD
II 5 I 5";( <";28;e:"P8 !% ];8$!7 I$$ .;2"`D $! 0!T1-
.;"$A;4 8)(1T !"H 8D '+" 0""7"$
:A;4 '+G+(!+: <"2'HJ/
!% A'+G+(!;+: <";2'HJ/ ,%1H 8#$!;+2 <5! 1D 8e:"P8
8H ;"%$% ,"1" "20*!1D I+:5$ !% .;4 5"n6 <%J+8 2- 82%
<";2';HJ/ .;<;4"D0;8 1;Å$ <$!$% A;4 8+C# <"2A%!561(
<";2I+m#51/!;`+GT 1ÖH$ <$!$% 5 A5"# 'HJ/ 8+\4 8#$!;+2
.(3@);<)72 <1)#H !$;%8 8D 0$"1n
:"2,6 '+#2$ 5 0)HJ/ <"2, 0)"6
<";;2_;-"4 B";2';HJ/ V;P* !% :É$!"$ 5 9$1e#
www.SID.ir
Archive of SID
,"f$"4 ,"T38
B";2I+m#51/!;`+GT I;$$ 5$ s$ 12 <%$5!%"8 _%" .%!408
];;Ö8 â%%1;;T0;8 A;;;<2%<'$1"!;- <";;2<!";;#+D 8;;D 1;c<8
_;%" ";$ 5 I8';"JT 0</!)+*!\851# ñ7"D 8H GPIIb/IIIa
.%!;40;8 1+:!* ? %!""1D i5!;<* 8D 1c<8 8( GPIb/IX/V
!% ";2 I+m#51/!`+GT I$$ <5! 0)HJ/ <"2, 0)"6!:6 !!Cu
.(3>);<<H 1++Z# '*$ I`#8 9xJ)-$ I$$
B(HPAs)0;;)HJ/ 0;;="L)-$ <";;2, 0;;)"6 {;;b$5 !%
VP;* <";2I$1;f)<$$ ?";)D <5! s;+" 0;)"6 <"2_-"4
8;D :!( <"2I+m#51/!`+GT 8+GH .;"!408 o!7&8 'HJ/
<";21#$%51)2 ";2I$1f)<$$ .;"!$% |Ge# "2I$1f)<$$ A%$!""-
";)D 5 ";t:6 ;;d$5 1;$5 5% <$!$% B"1n <5! 0<+m#51/!`+GT
.;;"!$% 4";L#$ N;2 8;D '"x$5!H 1+n 9!!= 8D 8H ;<)72
!% ;;<H0;8 ";%:$ $! 0" 0)"6 0T3$5 B"t:6 0<e$ 1)T!'D à'U
N2$1;( $! ;;""f+: 8;D 4"L#$ ]D"b KMD ")D A1+c"5 8H 0:"d
{$";b5 5$ 0e+;*5 A%5;;&8 8P;*$5 "2A;"1+T I$$ .%5"*08
];8"`# â];Ö8 ,";7"$ < !;:!+D !% 8H ;<)72 4!G* 0:"L#$
5 ";%D B(5")*!#2) 4%"e# 5 N-5 N+81# B0<#$$ <"%D B0<+<U
.()j B)@);<4"D08 NC8 0:!G* 91U"C8
GPIIb ";D vx!;#e8 GPIIIa(CD61) B";2'HJ/ VP* !%
4"+G#5;"$ ,!a 0$"24!G* <5! "8$ .%!408 'tU (CD41)
";;D Ç";;= 9J;;Ñ7 <";;24!G;;* 5 ";;2';;*JD51\+( B];;*
;b"( "24!G* I$$ $.: .;"!408 'tU <1f$% I+m#51/!`+GT
B';HJ/ VP* !% %!U!8 CD41 <5! HPAs <"2_-"4
';+" ';HJ/ 0;="L)-$ <";2 , 0;)"6 Üt: .(32);<4"D08
.'*$ .GP8 I$$ 5$ 8)(1T1D
5 A%!;D A;;+á+/ 0;)HJ/ <"2, 0)"6 <!$.Ti"" $;)D$ !%
<";2i";" <$!$% ";2,6 5$ <%$;;e# .';4$;" 0;="- <"<\8
';H$18 ";$ ";2A"f;1$"856 !% ,";85 N;2 8;H ;"%!D <%;e)8
A;;"$!- ,$!"#+D "$ I+t4"H 08"*$ "D 5 ;";4 91H 0#5"t)8
08";;*$ .;;7d 1;;D Ko 5 P1A <";;2, 0; )"6 .()));";;;4
];;8$!7 I; $$ 8; +G7 8;;H 0</!)+; *!\851# 8;;D J);;\8 ,$!";;#+D
A"f;1$"856 !% P1 .()2);";;4 <!$.;Ti"" ;<)4$% <%"D0)"6
3,,- 4";* !% $.;: .()3 B)+ B)>)';(1T i";" Zw <1f$%
,!;- 4";%)"$ 0"";CU {;#c8 ';HJ/ < !:!"!#$$ A51T!"H
!";L)-$ 5$ 5 %!;#" ';%($!8 <;$;U <!$.Ti"" "D (ISBT)
,";85 .;7d 1;D 9;G)M8 <"2, 0)"6 BA%1( A%"t)*$ HPA
!&
'(J/ < !:!"!#$$
8;H A;;4 O1;P8 .;"!;40;8 A%5 I+#M# 32---?3)----
VP;* HLA-I <";2, 0;)"6 I+f<;* 5 s\;* <"2A1+c"5
';:"-% (Releas)<5";*%$56 5 0;)HJ/ {;#c# !% B'HJ/
<";2, 0;)"6 ;;b"( 0;e+\/ ':"d !% "2'HJ/ .(3*);"!$%
Loading 5 , 0;)"6 8;X17 8;D !%";b 5 ;<;4"D08 HLA-II
";8$ .(3+ B3,);<);7+" HLA 4!;`:!8 <5! ;+)S/ (<1+T!"D)
HLA- %!U5 B0</!)+*!\851# 8D J)\8 !"#+D s$ 5$ 04!$'T
<5! HLA-II .;;;$"#"0;;8 O1;;P8 $! ";;2';;HJ/ <5! II
9xJ);;;-$ 8;;;D J);;;\8 ,$!";;;#+D <";;;2'+;;;*!$!"H"f8
';;Z8 5$ 0)+; *!$!"H"f8 CFU ';;1H !% 5 !; +#$1t+:51/!G+8
;+;*$ 5$ A%"t);*$ ";D .(33)%!;40;8 A;;$% 0e+\/ ,$!M)*$
VP;* 5$ HLA-I <";24!;`:!8 Bj 4%";e8 pH ";D s$1)+*
,"#)-";* s$1)+;*;+*$ .;"!;40;8 Ç.d "24!G* <"1n
5$ $! ,6 5 .; $1M# $! 4!;;`:!8 (";;)D)s\;;* A1; +c"5 i!;;*
.()-);<H08 $;U "t:6 I+f<* A1+c"5
Human Platelet Antigens )0)HJ/ 0="L)-$ <"2, 0)"6
: (= HPAs
<!;Z: 1;q" 5$ 0;)HJ/ 0="L)-$ <"2, 0)"6 OJP=$
I;$$ 5$ 0;-1D $1;$5 ;;*!0;#" 1;q" 8;D '*!% N2 0G+-
B4"+G#5;;"$ <";24!G;* ]Ö8 "24!G* 1$"* <5! "2_-"4
.(32 B3*);"!;40;8 A;;$% N;2 ";2'+*!t<: 5 "2'+*!"!8
<";2I+m#51/!;`+GT <5! 1;D !!H.;8 0;)HJ/ <";2, 0)"6
GPIa- B GPIIb-IIIa <";2I+m#51/!`+GT 1+q" 'HJ/ <"1n
B";;2I+m#51/!;;`+GT I;$$ .()3);;;"!$% !$1;;b GP IX/V 5 IIa
(CD41/CD61) .;);;72 ';;HJ/ <5! N;;C8 <";;2A;;;"1$./
BI+)`"51;;;\+( B, !;;;<$1\+( <$1;;;D A;;;;"1$./ GPIIb-IIIa
!% 0;#C8 K;%" 5 ';*$ ;"$1\G$5 ,!( ]8"7 5 I+)`"51)$5
%5;;;d .(3>);;;<H0; 8 ";;t$$ 0; )HJ/ (Aggregation){;;#c#
';HJ/ 1;2 <5! 1;#$%51)2 I;$$ 5$ %;7 2----?*----
, JH 8D 4"L#$ !% GPIa-IIa (CD49b) .()))%!408 A;$%
A;$% '+" T <"24!G* <5! B"2'HJ/ 1D A5J7 5 %!$% K%"
A;;;"1+T GPIb/IX/V (CD42b/CD42a/CD42d) .%!;;40;;8
8;D ';HJ/ 4";L#$ !% 5 ';*$ ;;"$1\G$5 ,!;( ]8"7 0G=$
%5;;;d .(3,)%!$% ';:"-% A;;$% .+;*6 :51;7 i!+G#5;;"$
A;;;$% ';;;HJ/ 1;;;2 <5! GPIb/IX/V 5$ 8M;;;7" )2---
www.SID.ir
Archive of SID

EF !"CD B3 A!"#4 B, A!5%

1);1+D !!;(5 5$ 1+n .'*$ b 5 a ]`4 5% <$!$% "2, 0)"6
%!;U5 (";2];:6)0" 4"`4$ I$$ I+D <1f$% 95"t# Ba i1(
95";t# 8D 1c<8 8H '*$ 0:6 5"D s$ !% 95"t# I$$ .%!$%
.%!;;40;8 b 5 a 4"`;;4$ I+;D 8;;<+86 ;+;*$ s;$ VP;;* !%
N);7+* <$!$% HPA-15 5 HPA-5 ";# HPA-1 <";2, 0)"6
]`;4 5% <$!$% s$ 12 5 A;4 8)-"<4 (biallelic) 0G:6 5%
.(3 45;U)()> Bj-);<)72 b 5 a
,$%$5!;;" ,!;;+#$$!:6 0</!)+;;*!\851# 551;;D !% : HPA-1
B (NAT; Neonatal Alloimmune Thrombocytopenia)
PTP; Post-Transfusion ),!;- 4";%)"$ 5$ R;/ <$!!;/!!/
.%!$% K%" 0)(J/ '85"%8 5 (Purpura
3,+ A"f$"U !% I$5!)+* "D I$;+#+# 0<$'f$"U ]+:% 8;D
B HPA-1 :4";Ö8 <$1;D);";;4 A%$% ,";1" %$;;7$ ";D 9;1H
<$1;D B HPAs N;7+(!!80;G/ ,;;4 _M;18 "D .(HPA-2
;;"%!#" A%"t)*$ (a , b) sa!H Ç51d 5$ "2]:6 ,%$% ,"1"
Ç1d 5 1)1+D 0"$5$1( "D ]:6 1f""$"#" a Ç1d 8H <!&" 8D
4";Ö8 <$1;D .()2);;4"D0;8 1)#H 0"$5$1( "D ]:6 1f""$"#" b
!% 8;H ';*$ A;;4 9;1H , I+;:5$ A;<2%,"1" HPA-1a
5 ";2, 1$";* .%!$% <1#x";D !!;(5 ,");*!/;+t* '+e#U
w Ç1d 5$ .;"!408 :J/$ 0CD"18 <!$.Ti"" "D "2, 0)"6
8;H ';*$ A;;4 A%"t);*$ HPAs 5$ 0-1D <!$.Ti"" !% '+"
.()2 B)* B),);4"D A;1" $;+/ "2 , 0)"6 I$$ 8+G7 <%"D0)"6
N;7+(!!80G/ 9;4 8D 0)HJ/ <"2, 0)"6 N7+(!!80G/
5$ 0-1D %!!8 !% HPA , 12 .;4"D0#" HLA <"2, 0)"6

(,) ?,/);<&'( 0&,6$;< ! X&S+I2 :) O#-b

HPA Q<9.J 6$;< ! 6.e0#1(/f.*9 !&78&b ;2#>/2#1& !&78&b 38.2! 0&,-.J4 X41..d0 68c78&b 0&,Z&
3a Leu 33 ZW 1a , PlA1
HPA-1 IIIa (CD41) 3>
3b Pro 33 ZW 1b, PlA2
)a Ther 145 Kob
HPA-2 Ib6 (CD42) 3>
)b Met 145 Koa
ja IsoLeu 843 Bak a, Lek a
HPA-3 IIb (CD61) 3>
jb Ser 843 Bak b
@a Arg 143 Yuk b , pen a
HPA-4 IIIa (CD41) 3>
@b Gly 143 Yuk a, pen b
2a Glu 505 Br b , Zav b
HPA-5 Ia (CD49) 2
2b Lys 505 Br a , Zav a
HPA-6w ? IIIa (CD41) 3> ? Ca , Tu
HPA-7w ? IIIa (CD41) 3> ? Mo (a)
HPA-8w ? IIIa (CD41) 3> ? Sr (a)
HPA-9w ? IIb (CD61) 3> ? Max (a)
HPA-10w ? IIIa (CD41) 3> ? La (a)
HPA-11w ? IIIa (CD41) 3> ? Gro (a)
HPA-12w ? Ib (CD42) )) ? Iy (a)
HPA-13w ? Ia (CD49) 2 ? Sit (a)
HPA-14w ? IIIa (CD41) 3> ? Oe (a)
32 a Ser 703 Gov b
HPA-15 CD109 +
32 b Tyr 703 Gov a
HPA-16w ? IIIa (CD41) 3> ? Nak (a)

!!
www.SID.ir
Archive of SID
,"f$"4 ,"T38
'85"%8 !% ,6 b i1( 5 PTP 5 NAT !% : HPA-3
I$;+#+# "D I+"$!T 0<$'f$"U 'G7 8D .;"!$% K%" 0)HJ/
0:$!# !% I+*!:5'$$ 8<+86 ;+*$ Bi!" )+)) '+eb!8 !%
'*$ A;4 I+1""U HPA-3b !% I$1* "D HPA-3a !% *@j
5$ %2) !% HPA-3b 5 %@* !% HPA-3a , .(+)
.(j))'*$ A;4 A;$% !!1H !% ,!- ,"T;<<($;2$
';;;+eb!8 !% .%!$% ';;;:"-% PTP 5 NAT !% : HPA-4
ñ;7"D 5 8;)(1T !$1;b I+"$!;T <";U 8;D I+;"%6 i!" 2)+
I+;7$JT ";D HPA-4a 3@j 0:$!;# !% I+;" !6 0$";U8;D"U
HPA-4a i1;( <$!$% ,");*!/;+t* 5$ %,, 5$ K+D .%!408
HPA-4a ;;X <"2<%"D0)"6 ;*!08 1q" 8D $.: .(+);<)72
!% , I;$$ !!;(5 .;;"!$;" '+#2$ 0)HJ/ '85"%8 551D !%
.(j));4"D08 %3-- B,$1C# 1C4 ,!- ,"T;<<H$;2$
3+@* ';+eb!8 !% I+"$!T "D I+"%6 0<$'f$"U : HPA-5
2-2 '+eb!8 !% 8<+86 ;+*$ s$ !% ÇJ)-$ 8D 1c<8 ,6 ,
(;+*$ s+8"#!GT) HPA-5a ]`4 "D (I$'+:) HPA-5b ]`4
HPA-5b , 5 %,, !% HPA-5a , .(+ Bj@)'*$ A;$%1T
A;;;$%1T 0!$';;T ,$1;;C# !% ,!;;- ,"T;;;<<H$;2$ 5$ %3 !%
.(j))'*$
,")*!/;+t* !% NAT %"c$$ 0G=$ ]8"7 I+85% HPA-5
,$!;;<7 8;;D HPA-5b 5 HPA-la .()>)';;*$ A;;;4 8)-"<;;4
8;D 5 ;;"$A;;4 8)-"<;4 0)HJ/ <"2, 0)"6!:6 I$1#$50<#$$
';;:"-% NAT 0<+:";;D %!$!;;8 5$ %3- 5 %*2 !% .;;+#1#
<5! A";;;;f$"U 3---?)--- <$!$% HPA-5 .(3>);;;;;"!$%
.(32);4"D08 "2'HJ/
5 A%!;D HPA-5 8D"18 ,6 8+G7 ,!+*$'+"!#$$ : HPA-15
'+eb!8 !% .;4"D08 HPA-1a 5$ R/ 5% I$$ 0<+:"D '+#2$
8;D 1;c<8 I$5!)+;* <";U 8;D I+"%6 0<+1""U Bi!" )3-*
!%)I$551; +# 8;;D (GOVb "; $ HPA-15a !%)I$1;;* ]$;;;\#
1$";* ÇJ- 1D HPA-15 .'*$ A;4 (GOVa "$ HPA-15b
<5! (CD109)A1;;+c"5 s;;# <!")-";;* <5! B";;2 HPAs
<5! ";2,6 1;D A5J;7 5 ';*$ 8)(1T !$1b "2'HJ/ <"1n
0:!G;* <"2A%! 5 "2]* 4"+G#5;"$ BA;4 4"e( T <"24!G*
5$ 8M;7" )--- %5;d .() ]ä4)%!408 A;$% N2 <!!8!#
8;D ,6 b5 a 4"`;4$ .%!$% %!;U5 ";2'HJ/ <5! HPA-15
,"T;;;<<H$;2$ !% 5 ,");;*!/;+t* 5$ %+- 5 %*- !% .; +#1#
!'
'(J/ < !:!"!#$$
(,,))*<+2 0&,6.e0#1(/g.*9 0#" ;<`'( 0&,6$;< ! :)3g(
";D HPA-la i1;( jj ';+eb!8 !% I+;*!: 8<+86 ;+*$ Bi!"
%)/2 .()>)';*$ A;4 I$'f$"U HPA-1b ]`4 !% I+:51/
A%5 I+; #M# .;<);;72 HPA-1a ;;;b"( ';;*!/ ;+t;;* %$1;;($
<%";D0;)"6 ;b"( 8H HPA-1a ;b"( %$1($ I)("$ <$1D %!408
A%!;D '+;*!t<: 5 ';HJ/ B';81b 4!;\GT <"2, 0)"6 ;X
$;;;2$ 32--?)--- %5;;;d B;<;4"D ';+" 0;;t<8 anti-CMV5
A51;T ";D %1( s$ ,%1H $;+/ <$1D .;"!4 0*!1D ;$"D A;<<H
(0;t<8 HPA-1)';\Ö8 HPA-1b 8;H 0;t<8 Rh 5 O 0"!-
HPA- <$1D ;$"D $! A;<<H$;2$ 32---?)---- %5;d B;4"D
,!;- ,"T;<<H$;2$ !% HPA-1a !!(5 .(3>)%!#" 0*!1D 1a
.(j));4"D08 %) %5;d !% HPA-1b 5 %,* ,$1$$ !%
K;%" 0;)HJ/ '85"%8 5 NAT !% , 0)"6 I$$ : HPA-2
I$'f$";U I+#+# "D I$5!)+* ,6 i!" 2)@ A"f$"U !% .%!$%
I+"!+)8 8<+86;+*$) HPA-2b ]`4 5% %"c$$ 8D 1c<8 5 A;4
!% I+"!;;;p1# 8<+86;+;;;*$) HPA-2a 5 (3@2 ';;;+eb!8 !%
!% HPA-2a 0;" !!;(5 .(j@)'*$ A;$%1T (3@2 '+eb!8
%@+ HPA-2b 5 %2@ ,$1;;$$ !% ,!;;- ,"T;;;<<H$;2$ I+;;D
.(j));4"D08
;"!$% !!Ñd GpII b / IIIa <5! 0)HJ/ <"2, 0)"61Ö($
HPA , -1, -3, -4, -6, -7, -8, -9, -10, -16 : ];;8"4 8;;H
5 GPIb/IX/V <5! HPA-2 5 HPA-12 .;<;;4"D0;8 11,-14
!$1;;b GPIa/IIb <5! (HPA-5,13)0;;)HJ/ <";;2, 0;;)"6
.(3 ]ä4);"!$%
www.SID.ir
Archive of SID

EF !"CD B3 A!"#4 B, A!5%

8;;D 'H!;;GT '; $"C" !% 5 ;<;;4"D0; #" 'H!;;GT 5$ , !;;`+GT A;;4 0!$';T %2j 5 %@> !% .;+#1# 8;D ,$1;C# !% ,!-
0;/ 9")Hx 'qGn 5 %!408 ]$;\# 9")Hx 5 s+)Hx;+*$ .(32 Bj))'*$
,";`8$ ];+:% 8;D .;D"$08 K$$'($ 0)HJ/ A%!561( <!$;Cf"
BA%!561( 0`+)*J/ 87+H <"2A!$!$% |$1/ 5$ ,3+7H$ %5!5
.';*$ ,"7`$ v"\$1%# ,3+7H$ Ç1L8 5 9")Hx ;+:!# ,$'+8
;<;4"D 08 'H!GT '+:!`+GT ]="d , 5!;+2 ,!$ 5 9")Hx
K2";H ,6 pH BNH$1;)8 ';HJ/ A%!561( <!$;Cf" 0/ $.:
<% B!+#$;+;7H$ N;7+:!D")8 0;/ .%%1T08 <;+*$ 5 ;D"$08
$! A%!561;( <1(";D Ä";*$ 8;H %!;408 ;+:!# ID1H ;+7H$
pH B%!$% %!;U5 9";<D1`+D 8;H 0""85 "# 5 ;2%08 ]+`1#
,$';+8 K$$';($ ";D ";8$ ;""808 'D"Å +/* 5$ K+D "# A%!561(
.;;<H08 '($ 1)1+D pH B9"<D1`+D 1$"-l Ç1L8 5 9")Hx
ñ7"D B'(J/ A3$5 01-1a <"21`+4 "D 'HJ/ <!$;Cf"
?";;;)D 8);;;*!+/ ,;;;;4 %$56 5 CD62P ,$';;;+8 K$$';;;($
<";;24!;"$1T 5$ (PF4)0;)HJ/ @ ];8"7 5 I+:!;D!GT!\851#
LDH V;41# "D I+<a N2 .(j B@ B3j)%!408 0)HJ/ <"t:6
B1`+4 9"H1d 0/ ;2%08 ,"1" 8H '*$ A$1#2 0:55!)+*
0;4"" 'H1d 1D A5J7 .%1+T08 9!!= 0)HJ/'+: <!$;%8 (h) CD109 0#" ;<`'( 6$;< ! :/3g(
";2';HJ/ ,A%!561( 8+C# <$1D ,%1H !t$1)""* "D B1`+4 5$
8;D 1c<8 8H ;"1+T08 !$1b (stress shear )K;<# Y1e8 !% ;4 0$"*"<4 GPIIIa <5! 1D <;$;U HPA )--* 4"* !%
<";24!"$1T (release)<5"*%$56 5 LDH s+:55!)+* 8+GM# i";;" Va , 0)"6!;;:6 I; $$ .(j2)';;(1T i";;" HPA-17w 8;;H
9$1;++Z# 5 <%";%e"$ <"2!!)H"( ,;4 4"e( .%!408 0)HJ/ !!;1H 5$ 0)+8!b !% (a i1() HPA-17w 0G:6 !!(5 .'4$%
<";;2.+; *6 1;;f$% 5$ '; +" ';;HJ/ 0$";;1n ,!)G`;;*$!)+* A;;$% %$1;;($ % 3-- !% 5 ';;*$ A;;;4 A%5 I+;#M# 3 I+;a
0;)HJ/ <"2A%!561( <!$;Cf" 0/ (platelet lesion)'HJ/ .(j+)%!408
I+;)H$ B,!;- s;""D [$$14 !% 'HJ/ <!$;Cf" 0/ .'*$
]L)8 I+m#51/ B'HJ/ <!$;Cf" 55! + 0/ .%!408 8$'c# :,!- s""D !% 'HJ/ <!$;Cf" 0/ 9$1++Z# ()
0:!;`:!8 ,55 ";D 9x!L&8 5 A;4 8$'c# 1)1+D I+)H$ 8D ";2'HJ/ 0T%!:6 ,"`8$ I+$"/ <"8% !% <!$;Cf" 8a1T
9";H1d ";$ 5 !t$1)"";* 0;/ K<;# .;;<H0;8 %";c$$ NH ";2';HJ/ BI+$";/ <"8% !% <!$;Cf" 0/ "8$ ;<H08 ;<H $!
B';*$ i5x ';HJ/ <!$;;Cf" 5 8;+C# <$1;D 8H 01-1a B3j);;<2%0;8 ';*% 5$ $! %!;- <51H ]`4 5 A;4 4"e(
4";e( BI+;)H$ 8$'c# 5 0:55!)+* LDH <5"*%$56 1D A5J7 'HJ/ <"1n 0fa!"/s$ B"81* !% 'HJ/ <!$;Cf" .(3-
4";e( I+S:";H .;"!;408 ñ7"D N2 $! (Calpin)I+S:"( ,;4 B';HJ/ ,!)G`;*$!)+* !% 1;++Z# !";C8 "D .;2%08 1++Z# $!
8;$'c# 8G+;*5 8;D 0;)HJ/ <"2]`+#!"/ ]+`1# ñ7"D A;4 1$.;;/,";;`8$ ";;2';;HJ/ 9;;;8 0"x!;;/ <!$;;;Cf" ,";;`8$
.(j B@)%!;40;8 ,!)G`;*$!)+* <";2I+m#51/ 1$"* 5 I+)H$ !% %";%e"$ ;;X %$!;8 8;D 'H!GT ,%5'($ 'G7 8D .(3-)'*$
9!!;= 8;D 9;G)M8 <";2'+;*!T")"6 8;D "2'HJ/ &*"/ NH$1;)8 <"2'HJ/ !% 'H!GT 'qGn B<1+T,!- <"287+H
]+`;;;1# .;;;;D"$0;;;8 K2";;;H (Aggregation){;;;#c# !% .';*$ s;$ !:!$'+( ';qGn 1;D$1D ^<;/ A;;4 8+C# A5"#
1c<8 B<5"m#51/ 8$'c# 5 'HJ/ <"1n 5$ "2]`+#!"/51`+8 ;;+:!# 8;D !%";b ";2';HJ/ B(in vitro),;D 5$ }!"- [$$14
!(
www.SID.ir
Archive of SID
,"f$"4 ,"T38
K$$';;($ 5 %";;c$$ B;;;2%0;;8 <5! NH$1;;)8 <";;2';;HJ/
";2,6 ;;+:!# A;#7 {\<8 8H ;4"D08 9G)M8 <"2I$"H!)$"*
.;<4"D08 0)HJ/ <"2A%!561( !% A;""#+b"D ;+t* <"24!\GT
8;+C# NH$1;)8 0:!\GT A%!561( <5! 1D A;4 i"c"$ 8e:"P8 !%
045!86 <$8%P<8 ,!- 4"%)"$ A"f$"/ !% PRP 05! 8D A;4
;;4 _M;18 B3j*2 4";* !% (4";=5 A"f$"/),$1C# ,")*$
<!$;;Cf" 55! j 0;/ BA;1" 1)G+( A%!561( !% IL-8 'qGn
<1+Ö`# '+:"e( 8a1T '+" "8"T 8e4$ KD"# 5 ;D"$08 K$$'($
5$ ";8$ ;2%08 !$1b 1+Å"# '&# $! A;""#+b"D ;+t* <"24!\GT
0;/ '+" TNF-6 'qGn .(j,);<H0#" <1+T!GU IL-8 ;+:!#
A;;$;" 8e;;4$ 5 A;;;1" 1;;)G+( A%!561;;( !% <!$;;Cf" 55! j
!% TNF-6 K$$';($ {"";8 ";8"T 8e4$ KD"# .;D"$08 K$$'($
0)+*!`: A;<2"H <"21)G+( 5$ A%"t)*$ "8$ .%%1T08 i!* 55!
$! i!;* 55! !% I$"H!)$"* 5% 12 K$$'($ B<!$;Cf" 5$ ]\b
.(@-);<H08 !"C8
8;D A;4 8+C# NH$1)8 <"2'HJ/ !% IL-8 'qGn K$$'($
"8$ .(@3 B@))'*$ A;4 0!$'T 9!H0("D 5 R$51(6 05!
<!$;;Cf" 0;/ I$"H!)$";* I;$$ ';qGn ;;*!0;8 1q" 8D
';*$ 1)#H RPR 5$ B9!H0("D 05! 8D A;4 8+C# A%!561(
';qGn 8a1T ;"%1H 0!$'T ,$!"`#2 5 !"`1D .(@) B@j)
0/ PRP 5 BC 05! 5% 12 8D A;4 8+C# A%!561( !% IL-8
I;$$ ';qGn K$$';($ "8$ B;D"$08 K$$'($ <!$;Cf" 55! 8*
.(>);4"D08 1)#H 9!H 0("D 05! !% I$"(!)$"*
: 0)HJ/ <"2, 0)"6 0*!1D <"205! (j
];+:% 8;D < !:51;* 05! 8D 0)HJ/ <"2, 0)"6 I++e#
%5;;;&8 ,";;7"$ !% .;;*"<8 <";;2i1;;* 8;;D 0;*1)*% i;;;7
;;X <";2<%";D0)"6 <$!$% "2i1*0)"6 5$ <!"+7D .;4"D08
%!;40;8 ];="d 0"";<+#/$ ]D"b 1+n ^$")" 5 ;<)72 HLA
";D 0;)(J/ <"2 , 0)"6 É!" I++e# B ,- 82% ]$$5$ "# .()))
<";2i1;*0;)"6 5$ 8;H ;408 i"c"$ s$ !:51* <"205!
8);4$% '$%5;&8 05! I$$ .;408 A%"t)*$ monospecific
HpA-1a I+;+e# 8;D !%";b [;%( ";2A"f1$"856 5$ <!"+7D 5
;;"!$% 0;#H 0)+7+" !"!#$$ B"2 HPA 5$ 0-1D .(3>);"%!D
"8$ .(j-);<)4$;" 0\*"<8 '+t+H A;4 ;+:!# <"2i1*0)"6 $.:
,";`8$ B9;G)M8 <"2<%"D0)"6 4""!GH!"!8 %"c$$ "D v"c$!;#
')
'(J/ < !:!"!#$$
<!;* 5$ .%!;40;8 'HJ/ <"1n !% GpIIb-IIIa K2"H 8D
I+m#51/!`+GT I$$ !!Cu K$$'($ 1D 0<\8 0$"2 0!$'T 1f$%
<";2]`+#!"/51`+8 .;4"D08 O1P8 "2'HJ/ <!$;Cf" 0/
5$ <!"+;7D 8;H ;<);72 <!;b <";2'"x!T6!H51/ B0)HJ/
";U ,6 5$ .;<<H08 Ütd $! N:"* 'HJ/ 0`$ !:!+D ã$!-
<1+f"!;- <";28;7+H !% %";%e"$ ;X ,$!<7 8D 9$1)+* 8H
5 N+;7GH 0;)+(1u 5% <";2,!+#";H 8D A%"8 I$$ B%!$% %!U5
0G;=$ <"2!!)H"(!H 5$ "2,!+#"H I$$ .%!408 ]L)8 N$'+<8
!";q)"$ .;<);72 ,";#GS#H s;+#"#$'"6 1+;78 <5"*4"e( !%
4"e( 8#$1)+* 0"!- <"2A%!561( !% ,"#GS#H N)7+* %5!08
4";e( 1;D <;2$!;4 C4a 5 C3a ';qGn K$$';($ "8$ %!1"
<";2A%!561;( 5 ,!;- <!$;Cf" 0/ ,"#GS#H N)7+* ,;4
B0`+);*J/ O!P;* 1;+q" 0U!";- %$!;8 .;<;4"D08 0"!-
0#";\+H1# .;;"!$% $! ,";#GS#H 0\<U 1+78 ,%1H 4"e( ,"`8$
<!$;;;Cf" ,";;85 !% ;+t;;* <";;24!;;\GT .;$1M# 0;/ 8;;H
0$";;"$!# v";#$l ';+" ;"!;;40;8 %";;c$$ 0"!;;- <";;2A%!561;;(
I;`#8 A;;4 4";e( ,";#GS#H .;"!$% $! ,"#GS#H <5"*4"e(
";20;*!1D .;4"D "2'HJ/ ,%1H 4"e( ]8$!7 5$ 0`$ '*$
'HJ/ <"1n !% C5b-9 5 C4b B C3a 'qGn ;"$A%$% ,"1"
";;D C4 5 C3 !!;;Ñd .;;;<D"$0; 8 K$$';;($ <!$;;;Cf" 0; /
!!;Ñd .;;"$A;;4 ';D"Å ";2';HJ/ VP* !% 1)8!)$"*!G(
K$$'($ 'HJ/ <!$;Cf" i!* 55! "# '\Ö8 C3 <"2'HJ/
Decay ) DAF !!;;Cu .;;;D"$0; 8 K2";;H Nc<;;/ 55! !% 5
VP;;* !% C3 !!;;Cu 9$5$!;;8 8;;D (Accelerating Factor
0;/ B";2';HJ/ <5! C3d à'U .;D"$08 K$$'($ "2'HJ/
Nc</ 55! ,"$"/ !% 5 K$$'($ 'HJ/ <!$;Cf" 45$ 55! 8*
9";ePb 1);1+D 8$'c# 5$ 04"" "$ xv "#)d$ 8H ;D"$08 K2"H
.;;4"D0;8 à";1n 5$ ";2 ,6 (shedding) 0';$! "$ ,"#GS#H
<!$;;;Cf" 5$ ];;\b 0)+;*!`: A;;;<2"H <";;21)G+( 5$ A%"t);;*$
,";#GS#H !"1D6 '+" (pre-storage leukodepletion)"2'HJ/
';&# $! 9;G)M8 <";2I$"H!)$"* ;+:!# "8$ ;<H08 4"e( $!
0;/ C4b 5 C3a ';qGn K$$';($ .(j>);2%0#" !$1b 1+Å"#
0!$';T single-donor <";2';HJ/ A55! ';t2 <!$;Cf"
";2I+7H!#J+(""6 %"$5 1$%"%8 A;4 O1P8 I+<a N2 BA;$%1T
.(j*);"!$% 1Å$ A;4 A1+-l <"2'HJ/ %1`G#7 K2"H !%
<!$;;Cf" 0;/ !% 8;H 0;ä$ !:!"!#$$ 9$1++Z# 1f$% 5$
www.SID.ir
Archive of SID
EF !"CD B3 A!"#4 B, A!5%
8%D";* 1;t" @ 8;H ,5 + 5 %1;8 3+)41;)<H A51T 5$ 1t" ))
.;;"%!D HLA-I ;X IgG <%"D0)"6 <$!$% B(;<)4$% 0fG8"d
<";2<%";D0)"6 !!Ñd I+%%&8 vJ\b 8H '*$ 0:"d !% I$$
,$!<7 8D $! IgM É!" 5$ HLA-A2, A3, B7, B8, B13 ;X
";8$ .;;"%!D A%!;#" 0!$'T (naturally)0e+\/ <"2<%"D0)"6
N:";* %$1($ !% <%"D0)"6 I$$ 8H ;4 _M18 8e:"P8 I$$ !%
B"2<%"D0)"6 I$$ 8H ;4 ,"+D 5 A%!D IgG É!" 5$ 41)<H A51T
;; +:!# <$1;;D .;<; 4"D0;;8 0; e+\/ <";;2<%";;D0; )"6 É!;;" 5$
â';*$ O1;P8 0#x"#)d$ HLA-I ;X 0e+\/ <"2<%"D0)"6
0T%$!""- <"2 8e:"P8 !% :I+<U 5 !%"8 ,!+*$'+"!#$$!:6 ?3
É!;;" s;$ !!;;Ñd 1;;D A5J;;7 B1;;7/ ,$;;;"51( !% 9;;G)M8
8;+G7 <%";D0)"6 É!" !"Ca â!%"8 <"2, 0)"6 ;X <%"D0)"6
?) .;;$%1T ';("$ B';*$ ";2,6 ;b"( !%"8 8H 0$"2, 0)"6
<%";D0)"6!#$ ?j 07<U Ä"## 0/ <%"D0)"6 &*"/ K$$'($
8H ;4 _M18 8e:"P8 I$$ !% . IgM 5 IgG B IgA É$!"$ 5$
%1;;( %!;;- <";;2, 0;;)"6 8;;+G7 HLA-I <";;2<%";;D0;;)"6
Ä51;$5 0D";$%! 8;D 8;U!# ";D .;<;4"D0;#" (<%"D0)"6!#$)
I; $$ s; +" 0; )"6 '2"\;;4 5 ,";;"6 5$ 1;;t" * !% 1)H";;D51)"$
A;;4 O1P8 B HLA-Dw4 4!`:!8 5$ 0$"2KMD "D Ä51$5
<%";D0;)"6 B AB 0"!- A51T ;X <"2<%"D0)"6 ;<""#2 8H
];8$!7 8;D 0;<#$$ &*"/ 4"\"% 8D vx"#)d$ HLA-I ;X IgG
s;+" 0)"6 1q" 5$ 8H 0$"2Ä51$5 5 "2<1)H"D ]Ö8 0P+&8
.(@,);"!408 %"c$$ ;<)72 HLA-I <"2, 0)"6 8D"18
<";2<%";D0;)"6 B HLA-I ;;X <";2<%"D0)"6 1D A5J7
.;"!;4 %";c$$ N2 "2I+m#51/!`+GT 8+G7 1D ;<"$!#08 0)HJ/
.(2-);<;4"D0;8 IgA 5 IgM B IgG É!;" 5$ "2<%"D0)"6 I$$
<$8;<+85 <";2<!";#+D .;7d 1;D ,!+;*$'+"!#$$!:6 É!+4
8;D ,";$J)\8 !% ,!+;*$'+"!#$$!:6 4";Ö8 <$1D '*$ 95"t)8
.(3,)'*$ 1)1+D ALL 8D ,"$J)\8 5$ AML
0<+:";;D Y!$!;;7 %";;c$$ !% 0; )HJ/ <";;2<%";;D0)"6!;;:6
5 (platelet refractory)0;;)HJ/
';;85"%8 :;;;<""8 0; tG)M8
Post Transfusion B PTP),!;- 4";%)"$ 5$ ;;eD <$!!;/!!/
|;$!'# Y!$!;7 5$ 1;+n 8;D ";8$ .;;"!$% ':"-% (Purpura
Immune ),!;+#$$ 0</!)+;*!\851# !% B0"!- <"2A%!561(
,!;;+#$$!:6 0</!)+;;*!\851# 5 (Thrombocytopenia : ITP
Neonatal Alloimmunized Thrombocytopenia : ),$%$5!"
'*
5$ 0;;-1D $1;;$5 ;;;4 !5;;;%8 ";;2 HPA 5$ 0;;-1D I+;;+e#
8;a 1;T .;";;4 ;+:!# HPA ;X <"2<%"D0)"6 4""!GH!"!8
B, 0;)"6 0$"Ñ( ]`4 'G7 8D "2<%"D0)"6 4""!GH!"!8 I$$
<5! A%!!;M" ';*% <";2I+m#51/!;`+GT "D K<H$5 ,"`8$
0:!;`:!8 9";7J/$ 8;D 8;U!# ";D .()));"!$;" $! "2'HJ/
V+&;;;;= _+M;;;;1# i5';;;;: 5 HPA N;;;;7+(!!80;;;G/
HPAs |+b% É!" I++e# ,6 885x 8H 0)HJ/ ,!+*$'+"!#$$!:6
5";n6 ,- 82% ]$$5$ 5$ 0:!`:!8 <"205! 5$ A%"t)*$ B'*$
,!+;;;*$;$1\+2 5$ ;;;;<#!"\7 ";;;205! I;;;$$ .(@@);;;;4
B(3,,3 4";;;* !%) ];;;:6 _);;;M8 <"2;;;;+#!mGH!"!f+:5$
0*!1D B(3,,@)Ä!`e8 <!$.T8P%" 05! "D ,!+*$;$1\+2
RFLP; Restriction )A;<<H %5;&8 <"2N$'"6 "D N7+(!!80G/
"D PCR B3,,j 4"* !% (Fragment Length Polymorphism
(PCR sequence-specific primer)R""`;* _)M8 1T5"n6
.(j) B@2)$'$x$ 05! 5 3,,@ 4"* !%
:;<`'( 0&, 0$&+ ;< !
<";2<%"D0)"6 :0;)HJ/ ;;X <";2<%";D0;)"6 É$!;"$ (3
;X "$ 5 (Anti- HLA Abs) HLA <"2, 0)"6 ;X 0)HJ/
8;H 0"$!";#+D 5$ 0;#+" .;<4"D08 (Anti- HPA Abs) HPAs
I;$$ 8;+G7 1;D B;;"!$% 0;)HJ/ <";2A%!561;( !1;`8 |$!'#
!% <$A;;4 11)<8 0!$'T .(@+);"!408 A'+"!#$$ "2, 0)"6
1;+-$ <";24";* ";# HLA ;X 0e+\/ <"2<%"D0)"6 %!!8
';G7 8;D vx"#)d$ HLA 8+G7 ,;4 A'+"!#$$ .%!D A;1" 8$$!$
";;$ 8;;""f+D HLA-A,-B <";;24!;;`:!8 8;;X17 5 05$%1;;/
;;4"D0;8 A;;"1+T T <";24!G* 8D (N+%)78 8X17)0$$;2$
É!;" 5$ 0$";2<%";D0)"6 B,!- |$!'# !"D ;<a 5$ R/ .(3,)
s;+" 0;)"6 <"2_-"4 8+G7 1D 0)+="- ;<a IgM 5 IgG
0;:$ s;$ 0/ "2<%"D0)"6 I$$ .(@>);"!408 %"c$$ ~1)18
ã$!;- 5 ;"!;40;8 %";c$$ ,!- |$!'# 5$ ;eD 8)t2 K4
<";24!\GT {#c# 5 ,"#GS#H <5"*4"e( B0)+7+7(!#!)$"*
)--* 4";* !% <$8;e:"P8 !% .(3, B@+ B@*);;"!$% $! ;+t*
!% HLA-I ;;X <";2<%";D0;)"6 0;*!1D ,!8$1+/ I/$ !%
;b"( N:"* %1( 3@, 5 s+#)7+*!#"#)$!$ Ä!/!: 8D ,"$J)\8
";2,6 5$ 1;t" @ 8;H ,5 3, ]8";4),!- |$!'# 0G\b 8%D"*
8;H ;;4 0!$';T B(%18 3j- 5 ;<)4$% 0G\b 0fG8"d 8%D"*
www.SID.ir
Archive of SID
,"f$"4 ,"T38
A%"t);*$ ,";7"$ <";2 I+D!GT!"!#$$ ;X 04!8 <%"D 0)"6 5$
;<t*!T '81b <"2 4!\GT B!1)74 ]d$18 5$ R/ 5 %!408
.%!;408 8("X$ 9$1td 8D 8/!D18 <%"D0)"6 "D A;4 A;+4!/
:!( 87!#c8 B0)HJ/ ;X <"2<%"D0)"6 %!U5 9!!= !%
';81b <";24!\GT 5$ <$8$x 5 ;\7a08 !!H.8 <%"D0)"6 8D
;;X <%";D0;)"6 1;T$ .%!;408 A;$% 9$1td VP* i"## !%
9!!;= 8;D ';81b <";24!\GT B;4"D 8)4$;" %!U5 0)HJ/
I;$$ .()@);;"1+T0;8 !$1;b A1;td [;*5 !% 0D!;*! 8#`#
K$";856 i"" '&# 5 ;4"D08 II 5"( <"2K<H$5 5$ K<H$5
Mixed Passive = MPHA)!+;*"/ [G)M8 ,!+*"<+#!GT "#2
I;$$ .%!;;40;8 A%1;;D i";;" ';+" (Hemagglutination Assay
0$";*"<4 <$1;D ,$!"`#2 5 "#"\+4 [*!# !"D I+:5$ K$"856
B05! I$$ '$%5;&8 .;4 A%"t)*$ 0)HJ/ <"2<%"D0)"6!:6
5$ 0;;)HJ/ 0;;="L)-$ <";;2<%";;D0;;)"6 '$";;## i;;;7
(HLA-I ;;X <";2<%"D0)"6 ]Ö8)0)HJ/ 1+n <"2<%"D0)"6
";D ";2';HJ/ BK$";856 i";c"$ 5$ ];\b 8;á""<a .;;4"D08
<";)D A1;+c"5 B;"!;4 !5";c8 s$1)+* ;+*$ "$ 5 I+H51GH
1;++Z# ,6 s;+" 0;)"6 <";2_-"4 5 A;4 .$1M# HLA-I
VP* HLA 8D "2<%"D0)"6 4"L#$ K2"H 8D 1c<8 5 ;<<H08
.(32);"!408 0)HJ/
05! I;$$ <";2K$"856 5$ 0;;`$ III 5";;( <";2K<H$5 ?
Modified Antigen Capture Elisa = )A;4 OJ=$ <$'$x$
<";2<%";D0)"6 "D '+G/ ;8"U 5"( 9H 8H ;4"D08 (MACE
,GPIb-IX ;X vJÖ8 0)HJ/ <"2I+m#51/!`+GT 5$ 0`$ ;X
0;)HJ/ ];""/ "D $! ,$!"#+D 5 41)<H i1* .'*$ A;4 A;+4!/
';+: ,!;)$1# ";D RS;* 5 A%!;#" !5";c8 8;""T$;U 8;:!: !%
<";2';+G/ 9$1;td 8;D $! ,6 0;$5! ';+: {$"8 5 ;<$"#"08
!% !!Ñd i;7 "$ <%"D0)"6 !!Ñd RS* .;<$$'($08 !!(.8
I:";ä:6 8;D ]L)8 i1* I8!+20)"6 s$ 5$ A%"t)*$ "D $! i1*
,";;1" <!!;;" o.;;U ';;p$1b 5 ,6 <$1);;7D!* 5 5"#"t;;7(
.(2- B22);<2%08
Monoclonal Antibody ) MAIPA K$";;;;;;856 ?
5"( <"2K<H$5 5$ (Immobilization of Platelet Antigens
0$";;*"<4 ';;+" 5 <1f:";;D1n 1;;D A5J;;7 8;;( ';;*$ III
É!;;" I+;;+e# ';;CU B0; )HJ/ 0; ="L)-$ <";;2<%";;D0; )"6
K$";856 8;D '\7" 5 %5!08 !"H 8D N2 0)HJ/ <"2, 0)"6
'"
'(J/ < !:!"!#$$
.;;"!$% K%" '+" 0$5!$% 0</!)+*!\851# 5 (NAIT or NAT
<";2!"#+D '" !#"/ !% '+" HLA ;X <"2<%"D0)"6 A5J7 8D
8;+G7 <;;"!+/ ';("D <!"#+D B'HJ/ '85"%8 1+q" 9G)M8
Transfusion Associated Graft ,!- 4"%)"$ 4"\"% 8D ,"D'+8
<!;$! %";d .+*6 ,( Versus Host Disease :TA-GVHD)
Transfusion Related : TRALI ),!;;- 4";;%)"$ 4";;\"% 8;;D
<";2K<;H$5 5 ,!;- 4"%)"$ 4"\"% 8D (Acute Lung Injury
8;)\:$ B;;"!$% ';:"-% ,!;- 4";%)"$ s+)+:!#2 1+n <$5.#
,"1" '85"%8 v"85': HLA ;X <"2<%"D0)"6 <$!$% ,$!"#+D
.(@ B2 B3, B23?2@);<2%0#"
$;;)D$ !% :0;)HJ/ <";2<%";D0)"6 0*!1D <"205! ()
5 ]`;18 B0;<( 1;q" 5$ 0)HJ/ VP* <"2<%"D0)"6 0*!1D
I+;<a .';4$% 5";+" 0LLM# 9$'+Cc# 8D 5 A%!D 1+T'b5
";D 0;)HJ/ 8;"!#" <%$;;e# 8;7$"%8 8;D %5;&8 0$"205!
1;;;D 0;;<)\8 <";;;2K$";;;856 v$;;;;eD ";;;8$ .%!;;;D 1f$;;;;`$
$';$x$ 5 0;*$!<#$$!$%$! B<1)8!)$";*!G( BR""*!!G(!"!#$$
.()@);";4 8)(1T !"H 8D N2
B"2'HJ/ 0T;<\7a 'G7 8D :,!+*"<+#!GT6 05! (9:$
B0"!;- <";2A51T I++e# !% ^$$! ,!+*"<+#!GT6 <"2K<H$5
0;%G# 1Å6;8 0;G+- 0;)HJ/ ;;X <"2<%"D0)"6 I++e# <$1D
<$!$% 0;e+\/ !!;/ 8;D ";2';HJ/ 8H "U ,6 5$ .;"!40#"
0; *!1D B;<);;72 à";;1n 8;;D ];;L)8 <";;2I+:!;;D!GT!"!#$$
I+:5$ .()@);4"D08 ]`18 'HJ/ 0="L)-$ <"2<%"D0)"6
,$!;<7 ';&# 0;)HJ/ <";2<%";D0;)"6 0;*!1D <"205!
i1;* B";2K$"856 I$$ !% .;"!408 0%G# I 5"( <"2K$"856
5$ ";$ 5 A;4 !5"c8 0e+\/ 5 N:"* %$1($ <"2'HJ/ "D !"#+D
];;Ö8 0; )HJ/ %1;;`G#7 8;;D y!;;D18 0$";;C" <";;2_-";;4
A%"t);;*$ ,!+;;*"<+#!GT6 5 {;;#c# B0:!;;"$1T <5";;*%$56
.(32 B)@);408
";D ';+" 1#;;$;U <";205! :;8"U 5"( <"2N)7+* (o
Solid-Phase = SPRCA);;8"U 5";( <"2N)7+* 5$ A%"t)*$
vx!#e8 .;"$A;4 8)(1T !"H 8D (Rec Cell Adherence Assay
R;/ .%!408 A;""4!/ "2'HJ/ "D '+G/51`+8 9$1td 9H
!% 8;H %%1;T0;8 8("X$ !"#+D i1* B"2'HJ/ ,%1H 'D"Å 5$
5 ;\;7a08 "2,6 8D B0)HJ/ ;X <%"D0)"6 %!U5 9!!=
BA;1" ]L)8 <"2<%"D0)"6 Ç.d 5 !1)74 ]d$18 5$ R/
www.SID.ir
Archive of SID
EF !"CD B3 A!"#4 B, A!5%
8;D ]L)8 <"2<%"D0)"6 0*!1D <$1D :<1)8!)$"*!G( (}
0;*!1D .%!$% %1D!"( i1* !% %!U!8 <"2<%"D0)"6 5 à"1n
Platelet Associated )'(J/ <"1n 8D ]L)8 <"2<%"D0)"6
";;8$ ';;*$ i";;c"$ ];;D"b <1)8!)$";;*!G( 05! 8;;D (IgG
5$ A%"t);;;;*$ .(2@);;;;;4"D0; ;;#" (specific)0;;;;="L)-$
Platelet Immune = PIFT)K$";;856 ";;$ <1)8!)$";;*!G(
0;)HJ/ ;X <"2<%"D0)"6 0$"*"<4 !% (Fluoresence Test
05! I;$$ !% .;;;4"D0;8 II 5";;( <";;2K$";;856 5';;U ';+"
!% !";#+D i1;* 5 41;)<H i1;* ";D A;;4 8)74 <"2'HJ/
,,!+;*"D!`"$ ]d$18 5$ R/ .;"!408 !5"c8 $'c8 <"28:!:
$;;U A;;1" ];L)8 <";2<%";D0;)"6 B!1)74 5 !t$1)""*
A%";8 ";D 8H IgG É!" 5$ 0""7"$ <%"D0)"6 RS* 5 ;"%1T08
A;;4 !$;"";1" (I+m*!!G( 9"""+*!+#5'$$) FITC '<*!!G(
<1)8!)$";*!G( A"f)*% 8G+*5 8D 5 8("X$ 87!#c8 8D B'*$
Ä";7d ";8$ 0;="L)-$ 1;+n 05! I;$$ .%!;408 0*!1D
5 HLA <";;2<%";;D0; )"6 '$";;## 8;;D !%";;b 0; :5 ;;;4"D0; 8
!% .(3>);;;4"D0; #" 0; )HJ/ 0; ="L)-$ <";;2<%";;D0; )"6
Ç.;;d %!!;;8 !% 0#";;e:"P8 B 3,,3 5 3,*, <";;24";;*
!% <1)8!)$";*!G( 05! 5$ A%"t);*$ 5 HLA-I <";2, 0)"6
<";2<%";D0;)"6 5 HLA-I ;;X <";2<%";D0;)"6 I+D '$"##
';+" 3j*j 4";* !% .(2>);";;4 i";c"$ 0;)HJ/ 0="L)-$
HLA-I ;;X <"2<%"D0)"6 0*!1D <$1D "8 [*!# <$8e:"P8
^$";)" 5 ;;4 i";c"$ <1)8!)$";*!G( 05! "D 0)HJ/ ;X 5
Panel )PRA K$"856 "D HLA-I ;X <"2<%"D0)"6 0*!1D
,"1" 8e:"P8 I$$ ^$")" .;$%1T 87$"%8 (Reactive Antibody
0#H!;:) 1;+q" 0"!- 9xJ)-$ 8D J)\8 !"#+D *) 5$ 8H %$%
<$!$% (%2j/>) 1;;t" @@ B(ITP Bs+);;*J/6 0;;#"6 B%";;d
<$!$% ';+" (%@j/,)1;t" j+ 5 HLA-I ;;X <";2<%";D0)"6
)> .;"%!D 0)HJ/ 0="L)-$ <"2, 0)"6 ;X <"2<%"D0)"6
%!;- i1;* !% $! <%";D0;)"6 É!" 5% 12 ,$!"#+D I$$ 5$ 1t"
PRA 5 <1)8!)$";;;*!G( 05! 5% I+; ;D 8;;;a1T .;<);;;4$%
HLA-I ;;X <";2<%";D0;)"6 0D";$%! !% 0D!- 0f)7\#2
1;q" 8;D 1;#Ä";7d <1)8!)$";*!G( 05! ";8$ %!$% %!U5
<"2<%"D0)"6 0D"$%! 8D !%"b [%( PRA 05! $1$5 ;*! 08
K$";856 PRA .(2*);;4"D0;8 ,";#GS#H N)7+* A;<<H4"e(
8;H %1;( ;<a <"2'+*!t<: ,6 !% 8H '*$ 0)+7+7(!#!t<:
'#
8;# ';+G/ s;$ 9$1;td 9H $;)D$ .;4"D08 1#Ä"7d 0G\b
GAM= )0!;8 <"2<%"D0)"6 8+G7 'D <%"D0)"6 "D $! Ç"=
!% Ç1;L8 ,";85 ";# '+G/ 5 A;""4!/ (Goat Anti Mouse
";D N:";* %$1($ <"2'HJ/ RS* .%!408 <!$;Cf" 4"áM$
8;D 0!"#;4 5 !;1)74 B<5"*$;U 5$ R/ O 0"!- A51T
i1;* .;"!;40;8 A%5'($ <1f$% '+G/ 9( !% 0<+e8 %$;e#
5 A%!#" 8D!`"$ 5 8("X$ i5% '+G/ 8D $! 41)<H i1* 5 !"#+D
.;;"1+T08 i"c"$ 'b% "D !t$1)""* 5 !1)74 ]d$18 RS*
8;D B!";#+D <"#*J/ "$ i1* !% <%"D0)"6 %!U5 9!!= !%
]=5 "2'HJ/ VP* GPs <5! HPA "$ HLA <"2, 0)"6
];#7 <!&" 8D "2<%"D0)"6 I$$ É!" I++e# 'CU .;"%1T08
04!8 É!" 5$ (mAbs)<"2<%"D0)"6 4""!GH!"!8 8H %!408
5$ R;/ ,0"";7"$ ';HJ/ GPs ";$ HLA <";2, 0;)"6 ;;X
s;$ 12);"!4 8D!`"$ 5 A%5'($ '+G/ 9$1td 8D <5"*|+b!
8;H (;"!;408 8("X$ <$8""T$;U 9$1td 8D "2<%"D0)"6 5$
";2';HJ/ VP* !% %!- 8D y!D18 , 0)"6 8D <%"D0)"6 12
Bã";- 1(";D s;$ 5$ A%"t)*$ "D 8Gd18 I$$ !% .%%1T ]=5
<";$"%D !t$1)"";;* ];;d$18 5$ R;;/ 5 A;;;4 ';+: ";;24!G;;*
';+: 5$ ];="d 0;$5! 4!;G&8 5 o!;*! 4!G* <"851)*$
8(";;X$ GAM ";;D A;+;4!/ 45$ ';+G/ 9$1;;td 8;;D 4!G;;*
"D 0:!G* '+: !% 0)HJ/ <"1n <"2I+m#51/!`+GT .;"!408
|;$1/ ,6 5$ 8;H A;4 A;+4!/ 0<+m#51/!ä+GT <"2<%"D0)"6
5$ R;/ .;;"%1T0;8 ]L)8 9$1td 9H GAM <%"D0)"6 8D
(8T53"!H) N$'"6 8D ]L)8 0""7"$ i1*0)"6 B!1)74 ]d$18
%";c$$ å;"! 1++Z# Bi5x <$1)7D!* ,%5'($ 5$ R/ 5 8("X$
';*$ 0;)HJ/ 0;="L)-$ <"2<%"D0)"6 %!U5 1f""+D A;4
.(N$$A%$% ,"1" j ]ä4 !% $! 8/!D18 N7+""ä8)(22 B2+)
MAIPA 78&2>! E.0&'( Q9. &f2 :, 3f(
www.SID.ir
Archive of SID
,"f$"4 ,"T38
1;#,$!;U ,$!";#+D !% ";8$ '*$ 1)1+D (HPA-1b) PLA2 5$
1);1+D 1D$1D !"Ca HPA-1b É!+4 B0\Gb Ä!)H!"t"$ 8D J)\8
<1;P- ];8"7 0)HJ/ N7+(!!80G/ I$$ 0#!"\7 8D .;4"D08
1;D 0;<\8 <;2$!;4 5 A%!;D 0b517 0\Gb <"2<!"#+D <$1D
];;&8 !% <%$;;;7"$ 5!;;\851# %";;c$$ !% ";;2';;HJ/ K;;%"
.(+-)%!408 A;$% R$551Gä*$51#6 ~J/ 0f)77T
HPA- 8;H ;4 _M18 '+" 3,,+ 4"* !% <$8e:"P8 !%
HPA- 5 %!408 ]=5 , !<$1\+( 8D <1)#H 9!;b "D 1b1b
!% <$8e:"P8 !% .()))'*$ A$1#2 %!"H!+8 Ä!)H!"t"$ "D 1b
B;<)72 HPA-1b ]:6 <$!$% 8H <%$1($ A;4 _M18 ,""!$
<!+GH <!"#+D 8D J)D$ K$$'($ 1P- 5 ;"!$% x"D ,!- !"1(
.(+3);4"D08 1)1+D "2,6 !% end-stage
<!"T5";* <";2, 0;)"6 ,$!;<7 8;D 0)HJ/ <"2, 0)"6
(minor Histocompatibility Ags; mHags) B0;71( 0)(";D
";D 0$";2, 9x!;L&8 mHags .(+) B+j);;"$A;;4 0%G#
A;;"1+T 5 A;<2% I+D 8H ;<4"D08 (s+(180G/)%;e)8 4"`4$
8;D B";2, 0)"6 I$$ 5$ ]="d <"2;+)S/ .;"!$% 95"t# ;"!+/
";24!G;* VP* !% MHC-II 5 MHC-I <"24!`:!8 8G+*5
$.;: .(+@);"!;40;8 0$"*"<4 T <"24!G* [*!# 5 8X17
;;"!+/ 5$ R;/ Y!$!;7 !% ';*$ I;`#8 8;( A;4 !!L#
.;<4"D 8)4$% K%" 5"*,!- <%"+<D <"24!G*
,0;*51$5 ];8$!7 1;D A5J;7 8;( ';*$ A;4 _M18
0;" N;7+(!!80;G/ B,";D'+8 8;D y!;D18 ];8$!7 5 0P+&8
!% ';+" (;<);72 0;)HJ/ <"2, 0)"6 <5"d 8H)"2I$1f)<$$
K;%" vJ\;b .;<;4"D 8);4$% K;%" C ';+#"S2 551\+( 8e*!#
y";\#!$ <1f$% 8e:"P8 !% v$1+-$ 5 %!D A;4 9"\Å$ HPA-5b
Ä51;$5 ";D ';"!t7 551\+( 8e*!# 1D HPA-1a/1b é+#!"
.(+2)'*$ A;4 _M18 C '+#"S2
i5!;<* 8D J)\8 ,$!"#+D <5! 1D "+:")$$ !% <$8e:"P8 0/
PLA1/A2 , N7+(!!80G/ I+D 8H ;4 _M18 '+" 'cCD
, I;$$ ";8$ %!$% %!;U5 8;PD$! 0%#7 ;$!5 R$5!\851# "D
, G20210A ,!+*"#!8 5$ 04"" R$5!\851# 8D J)D$ 1P-
.(++);2%0#" K$$'($ $! ,;+: 2 !!)H"( "$ 5 I+\851#51/
:0)HJ/ '85"%8 (3
BABO ;X <"2<%"D0)"6 !!Ñd B0)HJ/ '85"%8 ]$x%
'$
'(J/ < !:!"!#$$
!";#+D i1;* ";D $! ;<)72 9G)M8 HLA <"2, 0)"6 <5"d
HLA ;;X <"2<%"D0)"6 %!U5 9!!= !% .;<<H08 !5"c8
%!!;8 <";2'+;*!t<: <5! <";2, 0;)"6 8D B!"#+D i1* !%
';+: 8D 1c<8 8H A%!#" 4"e( $! ,"#GS#H 5 ;<\7a08 A%"t)*$
.(3,);"!408 0:!G*
I;$$ :(0;)HJ/ ];D"%)8 <!"T5";*)0;)HJ/ ç8Ä$1H (%
0$$;2$ <"2'HJ/ "D !"#+D <!"T5"* 0D"$5!$ <$1D K$"856
!5"c8 ,"T;<<H$;2$ <"2'HJ/ "D !"#+D i1* .%5!08 !"H 8D
';81b 4!;\GT 4"L#$ "$ 5 <1)8!)$"*!G( 5$ A%"t)*$ "D 5 A;4
BK$";856 I;$$ !% .%%1;T0;8 _M;18 8c+)" B;8"U 5"( 8D
8;D ';*$ I`#8 !"#+D %!- 'HJ/ "D !"#+D i1* <!"T5"*""
;;X <"2<%"D0)"6 B HLA ;X <"2<%"D0)"6 !!Ñd 'G7
I;$$ ";D B;;4"D 0"!;- <"2A51T ;X <%"D0)"6 "$ 5 HPAs
0$";*"<4 $! 0;="L)-$ <";2<%";D0;)"6 ,$!#0#" K$"856
%!$;;" A;;<<H$;2$ 5 !";#+D HLA I++e# 8D N2 <5"+" 5 %!#"
!";H 8;D ';HJ/ |;$!'# 0$!f1+/ <$1D K$"856 I$$ .(3,)
K$";856 B HLA <!"T5";* K$";856 "D 87$"%8 !% .%5!08
.;;2%08 '*% 8D $! <1#%"<)*$ ]D"b ^$")" 0)HJ/ ç8Ä$1H
8;D '7+" A$1#2 '+%(!8 "D 81+#2 K$"856 I$$ %1D!"H 8)\:$
K$"856 8c+)" "$ 5 x"D ,!+*$'+"!#$$!:6 ,$'+8 8H 0)b5 A3$5
.(32);4"D08 PRA> %2-
<";2<%";D0;)"6 0;*!1D <$1;D 8H 0$"2K$"856 ]`18
A5J;7 8;D .';*$ %!$;"");*$ ,$;%( B;"5!08 !"H 8D 0)HJ/
R;"$ !5$ %!$!8 !% 5 '*$ 1+T'b5 MAIPA ]Ö8 01$"856
.(2,)%!$;" 0$6!"H
:;<`'( 0&,6$;< ! Q9.R"/2;*( >4 ;(& 0&,0"&'.+
8;D %5;&8 0)HJ/ N7+(!!80G/ 0<+:"D '+#2$ "29;8 "#
%";;;c$$ 5 ";;;2<%";;;D0)"6!;;;:6 %";;;c$$ !% ";;;2,6 0$";;;"$!#
5$ R/ <$!!/!!/ B(NAT),$%$5!" ,!+#$$!#$ 0</!)+*!\851#
%!;U5 <;2$!;4 ";8$ .%!;D 0;)HJ/ '85"%8 5 ,!- 4"%)"$
%1;`G#7 1;D 0;)HJ/ N;7+(!!80;G/ 1+Å";# 1f"";+D 8H ;"!$%
<%;;;e)8 <";;2<!";;#+D 8;;D J);;D$ 1;;P- K$$';;($ 5 0:!G;;*
N;7+(!!80;G/ 8;H ;;"$A%$% ,";1" ";20;*!1D .()));<)72
!% ';HJ/ ';+:"e( K$$';($ "D B9G)M8 <"2I+m#51/!`+GT
(HPA-1a) PLA1 0;" É!+;4 8;a1T .;<4"D08 A$1#2 ,;D
www.SID.ir
Archive of SID
EF !"CD B3 A!"#4 B, A!5%
i5"%8 0`$ !:!"!#$$ 1q" 5$ "2,6 5$ 0-1D [%( "8$ ;"!408
;;X <";2<%"D0)"6 <$!$% ,$!"#+D 0#!"\7 8D .(+*);"!408
,";1" ';85"%8 0%$!'# <"2'HJ/ 8D '\7" v"85': B HLA
8;D ';HJ/ K$$';($ i;;7 B0)HJ/ '85"%8 .(+>);<2%0#"
;;;d$5 5% 0:$!;;)8 |;$!'# 4";;\"% 8;;D >/2 x 3-,/L 5$ K+;D
B1;1)<8 %";%e"$ B';"!t7 o";+n !% ABO '2"\4 "D 'HJ/
|;$!'# 1;Å$ .(+2);;4"D0;8 0:"f8!<GS;*$ 5 <'$1"!- B.#
5 'HJ/ %$;e# K$$'($ "$ 5 0<+:"D A;2"18 |$1/ 5$ 'HJ/
8\;*"&8 %!$!;8 0;-1D !%
(Corrected Count Increment)
_+M1# <$1D 0tG)M8 <"2K$"856 .(2j)'*$ !5;%8 CCI
&;*"/ 0D"$5!$ .(j 45;U);"!408 %"C<1+/ 0)(J/ '85"%8
5$ R/ 8%+b% +- "# 3- I+D CCI 8\*"&8 "D 'HJ/ |$!'# 8D
:%!408 è"&: |$!'#
(m2 BSA),;D VP* * |$!'# 5$ ;eD '(J/ %$;e# K$$'($ (* 3-33)
0%$!'# <"2'(J/ %$;e# |$!'# 5$ ;eD (* 3-33)
Post Transfusion ) PPR |$!'# 5$ R/ 'HJ/ '("$5"D
:'*$ 8\*"&8 ]D"b 1$5 4!81( 5$ (Platelet Recovery
,;D 0<+#M# Ncd * '(J/ %$;e# K$$'($
(;=!%)PPR = ()%)%&'( l8"c0 3+ c.i& jJ&( ;4&'<<4 38k$ :/ O#-b
0%$!'# <"2'(J/ %$;e#
o1;X ]="d B4"7T!'D %$1($ <$1D ,;D 0<+#M# Ncd
';*% 8;D >2 ml/Kg %;;7 !% i1T!G+H .7d1D "2,6 ,55
;eD '7"* s$ 0/ 4!\b ]D"b 0)HJ/ '("$5"D .(3-);$6 08
0%1;T !% 0%$!'# 'HJ/ 1#7 8#+" 5 %2-?%*- |$!'# 5$
.(+,)'*$ 55! @ %5;d A;"1+T ,!-
,$!";#+D 8;D ';HJ/ |$!'# <$1D 0tG)M8 <"2<3#$1)*$
5$ A%"t);*$ B05! s$ .%!$% %!U5 0)HJ/ '85"%8 8D J)\8
";8$ ;4"D08 HLA <!"T5"* "D ,"T;<<H$;2$ R$51( 'HJ/
0;*!1D HLA 1q" 5$ A!%:"D A;<<H$;2$ j--- 0:$ 3--- ;$"D
o";M)"$ 0;)b5 .%!#" 0""8!% '$"#d !"#+D s$ 5$ "# ;"!4
(HLA-matched) HLA <!"T5";;;* Ä";;;*$ 1;;;D ';;;HJ/
HLA '2"\;4 ";D ';HJ/ '("$!% <"<e8 8D v"8$':$ B;4"D08
.'7+" (HLA-identical)
<!"T5";* ";D ';HJ/ 5$ A%"t);*$ 9!51X 9!!= !%
!% . '*$ Ä1)*% !% A;<<H$;2$ I$1#!"T5"* !!q<8 B HLA
'%
];$x% .;<);72 0;$5!$% <";2 <%"D 0)"6 "$ HPA-3 5 HLA
45;U);"!4 0)HJ/ '85"%8 ñ7"D ;<"$!#08 '+" ,!+#$$1+n
';G7 ,$!;<7 8;D ,$!;#0#" $! <%1t<8 ]8"7 0#!"\7 8D .()
8;H <%$1;($ ;;<""#2 .(+>)%!;#" :J/$ '+eX5 I$$ %"c$$
B;<<H08 '("$!% $! ,6 <5"d <"2A%!561( "$ 5 '81b 4!\GT
I;$$ !1;`8 ';("$!% 4";\"% 8D 'HJ/ A;<<H'("$!% ,$!"#+D
0;%$!'# <";2';HJ/ 8;+G7 <%";D0)"6!:6 %"c$$ B"2A%!561(
0;/ ';81b <"24!\GT .$1M# 8D"18 N2 "2'HJ/ .;<<H08
s$ !:!"!#$$ 0T3$5 "8$ ;"!408 .$1M# 0<#$$ <"2;<$61(
ÇJ-1;;D .;<;;4"D0;;8 95";;t)8 "2;;;<$61( I;;$$ 0<+:";;D 5
0;)HJ/ <"2<%"D0)"6!:6 B'81b 4!\GT ;X <"2<%"D0)"6!:6
<";2';HJ/ <";%D ";8$ ;"!40#" %"d <"2K<H$5 8D 1c<8
K2";H $! ";2,6 0"";8!% 9$1;Å$ 5 ;;<<H0;8 NH $! 0%$!'#
8;$'c# "D "C<# 8" 0)HJ/ <"2<%"D0)"6 4"L#$ .(2j);<2%08
N2 $! 0)HJ/ %1`G#7 8`GD '*$ A$1#2 "2'HJ/ .$1M# 5
K<;H$5 !% ";2<%"D0)"6 4"Ö8 <$1D ;<2%08 !$1b 1+Å"# '&#
<%"%e"$ ];8$!7 "D "2'HJ/ K<H$5 5 B1f$;`$ "D "2'HJ/
.(+*);<$"#"08 ]-$;# (, !<$1\+()"#*J/
;8'84 1.m 324/5 ;8'84 324/5
0:"f8!<GS*$ ? HLA ;X <"2<%"D0)"6 ?
<'$1"!- ? HPAs ;X <"2<%"D0)"6 ?
'"!t7 "$ .# ? ABO ;X <"2<%"D0)"6 ?
0b517 ]-$% 11)<8 %"%e"$ ? "2<%"D0)"6!#$ ?
0%$!'# '(J/ N( !$;%8 ? 0%1T !% 0<#$$ <"2RäGS#( ?
'(J/ I+$"/ '+t+( ?
!"#+D (size) A5$;"$ ?
5 HLA ;X <"2<%"D0)"6 B0)HJ/ '85"%8 A;#7 ]8"7
|;$!'# 5$ R/ 0)HJ/ <"2, 0)"6 ;X <"2<%"D0)"6 v"#!;"
';;*$ I;;`#8 .(+,);;;4"D0;8 0;G\b 0fG8";;d ";$ 5 ,!;;-
8;D %!;- |;$!'# 8;8$%$ Nn!0G7 B HLA ;X <"2<%"D0)"6
<"2;d$5 ,"T;<<H'("$!% 5$ %j-?%>- .;"51D I+D 5$ %!-
A'+"!;;#$$!:6 HLA 8;;+G7 0(%";;L# A;;;<<H$;2$ 5$ B0;;)HJ/
www.SID.ir
Archive of SID

,"f$"4 ,"T38 '(J/ < !:!"!#$$

4";L#$ {"";8 5 A;+\;7a "2 "(51H"8 <5! B FCLR 8D IVIG <5! 0"";85 CCI ,$'+8 I$1#.*"<8 B0)HJ/ i5"%8 ,$!"#+D
Ç.;d 5 ";2,6 8;D <%";D0;)"6 "D A;4 Ä"7d <"2'HJ/ O1;;;P8 B2UX "; ;$ B1U B A .;;;*"<# 8;;;H ;;;;2%0;;;8
|;$1/ 5$ IVIG %1`G#7 1f$% N7+""`8 .%%1T08 "2'HJ/ .(@ 45;U);4"D08
"2é$"#!$;$$0)"6 .;4"D08 é$"#!$;$$0)"6 ; é$"#!$;$$ 8`\4
()%);<&'( %2#&52 H.+I0 ;,&7I8&2>! 0&,6/2>! :, O#-b
4";L#$ ];D"b KMD) Fab KMD "D 8H ;<)72 0$"2<%"D0)"6
.;;<2%08 K<H$5 "2<%"D0)"6 1$"* <"24!`:!8 (, 0)"6 8D
:;<&'( -: 0&,0$&+;< ! ;J"1+ !
';*$ 0$";2<%";D0)"6 <5"d IVIG 8H %!#" 'D"Å ;:!)41D PRA o
";D $! GPIIb/IIIa ;;X <";2<%";D0)"6!;#$ 1;Å$ ;<"$!#08 8H 0)(J/ ç8Ä$1(!#$ o

IgG <5";d 4""!GH0G/ Anti-D .;$"#" 0Ö<- "2,6 8D 4"L#$ 0)(J/ ,!+*"<+#!GT6 o

8;D D , 0;)"6 "D A'+"!#$$ 0t<8 Rh ,"T;<<H$;2$ 5$ 8H '*$ R""*!!G(!"!#$$ "D "2'(J/ 0*!1D o
:;<&'( 0&,6$;< ! ;J"1+ !
,"8!% !% Anti-D '+%(!8 ,$!"`#2 5 "8x"* .;$608 '*%
A;<<($;2$ / A;"1+T HLA I++e# o
<$8)72 s# <!$!-8""f+D N)7+* 0)D"b! !"C8 'G7 8D ITP
MAIPA o
0!$';;T $! A;;;4 Ä";;7d ';;81b <";;24!;;\GT [;;*!# 0)(J/ é+#!" I++e# o
.(+*);"%!#" 0"&9>&J 78&2>! !
]D"%)8 <!"T5"* o

1P >4 )*<+2 0&,0"&9>&J &+ %&'( _J&80 64c.2 : L O#-b CCI o

()h ?)%) HLA

:,!+#$$ 0</!)+*!\851# "$ ITP ()

&+ "&9>&J 0&,n.0/8R
3b"$
s+#"/!$;;$$ 0</!)+*!\851;# <$!!;/!!;/ B ITP 8;D vJ\b
HLA-);:1R "&'.+ ).T/0 5 ,x";7T!'D 0D"7)H$ <!"#+D B'+eX5 I$$ .;408 :J/$
A1/A3HLA- _J&80
((B8/B27)+ 5 0<+:";D 9xJ);-$ 1$";* ,5;;D ';HJ/ %$;e# "D ,"H%!H
HLA-A1,A3,B8,
, 0)"6 !"Ca <$!$% .;;4"D0;8 (A;;<2%<'$1"!- 9xJ)-$ 'U 8D)02"f1$"856
A
B27 !"T5"* i";" 8;D Ç!;2 4!5 8G+;*5 8;D 3>j2 4";* !% <!"#+D I$$
<$!$% "$ , 0)"6 ë$ ;b"( 5$ %,2 .;;4 A;;"$!- Marbus Maculosis Hemorhagicus
HLA-A1 ,B8,B27 B1U
I+e8"" , 0)"6 ë$ 5$ %2 5 IgA 5 IgM A$1;#2 ";$ 5 0$";C<# 8D IgG "$ ,$!"#+D
cross , 0)"6 ë$ <$!$%
HLA-A1,A3,B8,B7 B1X 8;D <!";#+D 0<+:"D N$J7 .;<)72 0$"C<# 8D IgM <$!$% "2,6
reactive
<$!$% 5 , 0)"6 ë$ ;b"( .;;4"D 0;8 0#"6 "$ 5 0/"M8 <"2<'$1"!- B01)/ 9!!=
HLA-A1,B8, B7 cross , 0)"6 ë$ B2UX 4";t/$ !% ,6 %";d É!;" 5 ,x"7T!'D !% <!"#+D I8'8 É!"
reactive A;;$% '"!t7 0G\b 8%D"* "D 5 4"* + "# ) 0<* A%5;&8 !%
HLA-A1,A3,B8, <!"T5"*"" %!!8 ë$ "D C
B35 .(32 B2j) %!408
HLA-A1,A32,B8, <!"T5"*"" %!!8 5% "D
B35
D ];;-$% I+:!;;D!GT!"!#$$) IVIG 5$ ITP ,";;8!% <$1;;D
HLA-A2-A28, 0(%"L# <!"T5"* "D
B7,B35
R 1;Å$ %!408 !!L# .(32)%!408 A%"t)*$ Anti-D 5 (<;$!5
4";;e( 0)D";b! !";C8 5$ 0;4"" ITP %!;\CD !% IVIG 0"";8!%
: 0$5!$% 0</!)+*!\851# (j ";;2 "(51H"8 <5! B(IgG 'D"Å KMD) FCLR A;"1$./ ,%1H
5 I$!"S2 B"t:!* <"25!$% BI$;+<+H/I+<+H ]Ö8 0$"25!$% ';+" '81b <"24!\GT 8D IVIG $1$5 .;4"D08 "2!$!-8""f+D 5
!% .;<)72 0</!)+*!\851;# 8;X!"7 <$!$% <;;+p!GH <J/ RBC - 8;7!#c8 5 ;<H08 Ä"7d $! "2,6 5 A;;4 ];L)8
'&
www.SID.ir
Archive of SID
EF !"CD B3 A!"#4 B, A!5%
!% -/@ 5$ 1#x";D <!!;" o.U .%%1T08 0D"$%! (Enz-Ab)
!!;Ñd BA;;4 !";C8 I$!";S2 8G+;*5 8;D 8;H PF4 9$1td
.;<H08 ;+$"# $! I$!"S2 8D 8)7D$5 <"2<%"D0)"6
!;+)H$!$%$! N$';* "D A;4 !$;""1" I+"!#51* ,;4 %$56 (o
<";2K$"856 5$ ,(Serotonin Release Assay) SRA i"" 8D
.'*$ I$!"S2 ;X <"2<%"D0)"6 0*!1D <$1D B I 5"(
8;D!`"$ !$;"";1" I+"!#51;* ";D N:"* 5 A5"# <"2'HJ/
i1* RS* .%!408 'HJ/ NH$1)8 <"24!"$1T %!$5 5 A;4
8;D!`"$ I$!";S2 %";$5 5 N;H <";2';qGn !!Ñd !% !"#+D
,6 8;;D I$!";;S2 B<%";D0;)"6 %!;;U5 9!!;= !% .%%1;;T0;8
<5";;*%$56 {"";;8 I$!";;S2 <x";;D ';;qGn !% 5 %;;;"!+/0;;8
8;D I$!";S2 N;H <";2';qGn !% ";8$ .%!;40;8 ";24!"$1T
!;+)H$ !;$%$! I+"!#51* <5"*%$56 ñ7"D 5 ]L)8 "2'HJ/
N;H ';qGn !% !;+)H$!$%$! %$!;8 %)- ,;;4 %$56. %!;408
!% ,;;;4 %$56 5 N;;H ';qGn !% ,;;;4 %$56 !";;C8 BI$!";S2
8;D 8)7D$5 <"2<%"D0)"6 !!Ñd 1f""+D BI$!"S2 %"$5 'qGn
.(32)'*$ I$!"S2
:(PTP),!- 4"%)"$ 5$ R/ <$!!/!!/ (@
A;"!;;;4 %5;;;;&8 %!;;;- 5 0"";;;CT"" 01);;;7T PTP
,$!"#+D !% |$!'# 5$ R/ 55! 3- 0:$ 2 0/ 0</!)+*!\851#
";$ 0fG8";d 0;/) ";2';HJ/ ,;4 Ä"7d 0G\b 8%D"* "D
Anti-HPA-1a !!;Ñd ";D 8X!"7 .'*$ (0G\b ,!- 4"%)"$
<%";D0;)"6 ;;*!0;8 1q" 8D "8$ .'*$ A$1#2 !"#+D i1* !%
1;;D A5J;;7 PTP !% .;;;"!$% ';;:"-% N;;2 HPAs 1$";;*
.;"!408 .$1M# N2 !"#+D <"2'HJ/ B0%$!'# <"2'HJ/
8;D (<%!;-)r!;:!#$ <"2'HJ/ .$1M# 5 PTP N7+""`8
<";2<%"D0)"6 8H ;*!08 1q" 8D "8$ '7+" _M18 0D!-
";;;$ 5 ;;;;"!$% 0)$!;;;+)H$!!#$ '+;;;="- BA;;;;4 ;;;;+:!#
1c<8 5 A;4 %"c$$ $!.T 9!!= 8D 0)HJ/ <"2<%"D0)"6!#$
"#;*J/ .;"!;408 0$$;2$ 5 <%!- <"2'HJ/ .$1M# 8D
4";%)"$ .;;"5!0;8 !";H 8;D PTP ,"8!% !% IVIG 5 R$51(
0(%";L# A;;<<H$;2$ ";$ 5 0;" 0;)"6 <!"T5"* "D "2'HJ/
.(32 B+,);4"D0#" 1Å68 0G+-
8H ;"%$% ,";1" 5 A;;4 i";c"$ 0;#"e:"P8 B ,- 8;2% !%
:J;;;/$ HPA-1a A5518$ 8H p1 "$) PLA-1 <"2, 0)"6
A1
'!
1;+n 5 8);7D$5 <"2<%"D0)"6 É!" 5% 12 B"20</!)+*!\851#
8;D 8)7D$5 1+n <"2<%"D0)"6 .;"!408 %"c$$ 5!$% 8D 8)7D$5
";2';HJ/ ";D ";2,6 K<;H$5 5 5!$% !!Ñd 8D <5"+" 5!$%
"2<%"D0)"6 '$"## 8D !%"b B0`$ !:51* <"2K$"856 .;"!$;"
%";c$$ 0"";85 5!$% 8;D 8);7D$5 <";2<%";D0;)"6 "8$ .;<)7+"
';HJ/ <5! ];8$!7 ";$ 5 ";2í!#0/$ "D 5!$% 8H ;"!408
ñ;7"D ";25!$% !!;Ñd !% ";2<%";D0;)"6 I$$ .;2% K<H$5
5!$% Ç1;L8 9;b!# "D vx!#e8 8H ;"!408 'HJ/ .$1M#
B0;$5!$% <";2<%";D0;)"6 0;*!1D <$1;D .(32)%!408 {(!
!% .;;"5!08 !"H 8D s$ !:51* 5 <1)8!)$"*!G( <"205!
<";;;2';;;HJ/ 5 !";;;#+D i1;;;* B<1)8!)$";;;*!G( 05!
!5";;c8 5!$% !!;;Ñd i;;;7 5 !!;;Ñd !% A%!!;;M"';;*%
,$!;#0;8 $! IgM 5 IgG É!" 5% 12 B05! I$$ "D .;"!408
.%1;( A%"t)*$ '\Ö8 41)<H <"2i1* 5$ ;$"D "8$ .%!#" 0D"$%!
4";Ö8 <$1;D %!$% ';+" 0$";2'$%5;;&8 05! I$$ A5J7 8D
8;;D 4";;L#$ <$1;;D ";;25!$% 5$ <!"+;;7D .;;*"<8 ';;qGn
5$ 5 ';7+" _M;18 A"f;1$"856 [$$1;4 !% B";2<%"D0)"6
A%!;D '+a"" 5!$% 8D <%"D 0)"6 4"L#$ %!$!8 0-1D !% 0$!*
B%!$!8 0-1D !% 0#!"\7 8D .;<H08 Ä"7d$ 1+n $! 05! 5
";2';HJ/ 8;D 8;H ;<);72 ,;;D !% 5!$% <"2'+:!D")8 I$$
5 I(!<+8");;;*$ ];;;Ö8) 0G;;;=$ <5!$% 8;;;" ;<\;;;7a0; ;8
<";24!;"$1T 5$ 8;H ) PF4 ";D I$!";S2 .(455";7H!)8"t:!*
%";;c$$ 5 A%$% K<;;H$5 B(%!;;4 0;;8 %$56 0;;)HJ/ <";;t:6
B IgA É!;" 5$ 0$";2<%";D0)"6 ;+:!# 8H ;<H08 <$87!#c8
R;/ .%%1T08 ]L)8 "2,6 8D 5 ;$"#"08 %"c$$ IgG 5 IgM
$! "2,6 5 ]=5 'HJ/ <5! FCLRII 8D B IgG "D K<H$5 5$
.%!408 ;+:!# I+\851# 8H A%!#" 4"e(
I;`#8 ';HJ/ ";D I$!";S2 87!#c8 "2'HJ/ 1D A5J7
";2,6 8D 5 A;4 ]=5 0b517 4"+G#5;"$ <"24!G* 8D '*$
8;D 8);7D$5 <";2<%";D0)"6 0*!1D <$1D .;""*1D .+*6 '+"
:%!$% %!U5 K$"856 É!" 5% I$!"S2
,6 !% 8;H B (III 5";( <"2 K$"856 5$ ) PF4 ELISA ?9:$
.;;"$A;;4 A;+;4!/ PF45 I$!";S2 87!#c8 "D '+G/ 9$1td
(3-- 9L)%";$5 1$%";%8 !!;Ñd !% 5 0$";C<# 8D !"#+D i1*
i1;* !% <%"D0)"6 %!U5 9!!= !% .%!408 8("X$ I$!"S2
8;T53<H ,%5';($ "D RS* 5 %!408 ]=5 I$!"S2 8D B!"#+D
www.SID.ir
Archive of SID
,"f$"4 ,"T38
HPA- ;X 0="L)-$ B <"24!G* 8e*!# 5 [7D 8D 1c<8
1;)#H 0)+;7+" !"!#$$ 'G7 .;"!408 <%"D0)"6 ;+:!# 5 1a
5$ 0;4"" vx";#)d$ (jj '+eb!8 !% I+:51/ <$!$%) HPA-1b
jj I+;*!: ";D 8;7$"%8 !% I+:51/ <5"d ;+)S/ 1)#H .*"<#
.()2)'*$ HLA-II 8D 4"L#$ !% (HPA-1a !%)
8;D ]$"## B HPA-5b ;X 5 HPA-1a ;X <"2<%"D0)"6
0$"*"<4 "D ,- 82% !% "8$ ;"!$% N$J8 0</!)+*!\851# %"c$$
8;;;H ;;;;4 _M;;;18 <;;;;eD <";;;20; ;*!1D 5 HPA-15
NAIT ;$;;4 %!$!;8 !% ';+" HPA-15b ;X <"2<%"D0)"6
B HPA-1a ;;;b"( ,";;"5 5$ %)- %5;;;d .;;;"$A;;;4 0$";;*"<4
"2,6 5$ %j- I+<U 5 ;<<H08 %"c$$ HPA-1a ;X <%"D0)"6
,$!%";8 !% <%"D0)"6 %"c$$ 0$""$!# .%1+T08 !$1b 1+Å"# '&#
41;;)<H HLA-DRB3*010 ];;:6 8G+; *5 8; D HPA-1a ;;;b"(
]:6 I$$ ;;b"( ,";"5 !% <%";D0)"6 ;;+:!# 4";#)d$ .%!40;8
.;4"D08 1)#H ;<)72 ,6 <$!$% 8H 0"""5 8D '\7"
;;X <";2<%"D0)"6 K$"856 02"f1$"856 0*!1D <$1;D
<!;;/ <";2';HJ/ ];D"%8 !% !%";8 i1* 0*!1D B HPAs
HPA-1,-2,-3,- <";2, 0;)"6 I++e# 5 (0)(J/ ç8 Ä$1()
!% .;<);72 8+;=!# ];D"b PCR-SSP 05! "D I$;:$5 5,15
,";8!% B0fG8";d 0;/ I+;<U <J)D$ 1P- 4"#)d$ 9!!=
,!;- 4";;%)"$ 5 IVIG B;;;+p51)*!`+#!!H Ç1;L8 "D !%"8
.(3>);<4"D08 i"c"$ ]D"b 0#d! ]-$%
<";2<%";D0;)"6 _+M1# !% A%"t)*$ %!!8 <"2K$"856
$.;: 5 ;<);72 ,"T;<<H$;2$ 5$ 'HJ/ 8+C# 1D 0<)\8 B0)HJ/
$! K$";856 I;$$ 8H <'H$18 5 A;<<H$;2$ '+e#U .7d 1D
];+\b I;$$ <5";*%!$;"")*$ .;<4"D08 1+Z)8 ;<<H08 A%"t)*$
.(>3);4"D0#" KMD'$"X! '+" "2K$"856
<5! <";;;2í!;;;#0;;;/$ A;;;;4 _M;;;18 v$1;;;+-$
EDTA 8;D '\;7" (GPIIb/IIIa) "$ 6(IIb)!(3)I+m#51/!`+GT
8;+C# <$1;D EDTA 5$ A%"t)*$ 9!!= !% 5 ;<)72 Ä"7d
'+;*"7d B MAIPA K$";856 !% A%"t)*$ %!!8 <"2'HJ/
5 %!;\CD <$1;D 0J;# $.: .(>));D"$08 K2"H K$"856
<"2;;+)S/ 8;D 0D"+);*% 8;D 1c<8 MAIPA K$"856 <"%#!$
HPA-1a A;;<<H ;;+G%# 8;H A;;4 (peptide aptamer)18")/$
{;(! $! K$";856 I$$ !% 'HJ/ 5$ A%"t)*$ 8D 5"+" 5 ;<)72
.(>3);<<H08
''
'(J/ < !:!"!#$$
8;D 0;)+(1u 5% ';\Ö8 <"2,!$ !!Ñd !% ;"!%"b (%!408
,!;- <";2A%!561;( !% 8;H , 0;)"6 I;$$ ;b"( <"2'HJ/
PLA-1 <"2'HJ/ 8D $! "2,6 5 ;"%1T ]L)8 ,;"!$% %!U5
<"#;*J/ !% 4!;G&8 v$12";u PLA-1 .;;<<H ]$;;\# '\Ö8
8;Gd18 !% {;b$5 !% 5 ';*$ ';HJ/ <5";d <";2A%!561(
<5";;*A%";;86 0;/ !t$1)"";;* 8G+;*5 8;;D ';;HJ/ .;$1M#
V+; X!# I; $$ ";;D .%!;;40; 8 %";;c$$ ,!;;- <";;2A%!561;;(
PLA-1 N:";* %1;( !% B,!;- 4"%)"$ 5$ R/ 0</!)+*!\851#
.(>-);$%1T 8+U!# ]D"b 0t<8
: (NAIT"$ NAT ) ,$%$5!" ,!+#$$!:6 0</!)+*!\851#(2
'81b <"24!\GT .$1M# 8D"18 B,6 !% 8H '*$ 08!;<*
<";2'HJ/ .$1M# 8D 1c<8 ,,$%$5!" s+)+:!#2 <!"#+D !%
.%%1;T08 (0<#$$ .$1M#)!%"8 <"2<%"D0)"6 [*!# ,$%$5!"
<";2, 0;)"6 ];D"%8 !% ';*$ I;`#8 !%";8 0fG8";d 0/
;;b"( !%"8 5 A;+*! ì!$ I+<U 8D !;/ 5$ 8H I+<U !"T5"*""
!!\7 'tU 5$ 8H ;<H ;+:!# IgG 5 A;4 A'+"!#$$ B'*"2,6
I$$ .%!408 <%$5!" "$ 0<+<U 0</!)+*!\851# ñ7"D 5 A%1H
8)-"<4 3,2, 4"* !% NCTx ,5 8G+*5 8D !"D I+:5$ 8X!"7
%5;d .;4"D08 A;"5 ;:!# 3)--- !% 3--- ,6 É!+4 5 ;4
.;;2%0;8 <5! 45$ <";20fG8";d !% NAIT %!$!8 5$ %2-
!% %!U!8 (0)+<+($)]$"## IgG !$;%8 .7d 1D 'HJ/ <"%D
';&# BÇ;2 , 0)"6 NH$1# 5 ,6 <"2A51T1$5 5 !%"8 i1*
8;Gd18 !% 5 HPA-la ;X <"2<%"D0)"6 .%1+T08 !$1b 1+Å"#
B";2, 0)"6 I$$ ;b"( ,$!%"8 !% HPA-5b <"2<%"D0)"6 ;eD
5$ ';;tU 5$ IgG !!;;\7 .;<);;72 NAIT ^;;$$! ];;$x% 5$
5$ 0;)(J/ <";2 <%"D0)"6 .'*$ !5;%8 N2%!"Ca <"2 8)t2
I$$1D";;<D .;"!;;40;;8 12";;u 0fG8";;d N2%'"";;4 8;;)t2
.(3>)%!;4 %"c$$ 0fG8"d ]$$5$ !% ;"$!#08 0</!)+*!\851#
, 0;)"6 I;$$ <$!$% <5 I+;<U 5 HPA-1a ;b"( <!%"8 1T$
,!;- 0%1;T %!$5 I+;<U <";2'HJ/ '*$ I`#8 B;4"D
%5";7D HPA-1a ;;X <%"D0)"6 "2,6 8+G7 <5 5 A;4 !%"8
HPA-1a .;;4"D 8);4$% 0\b$!;7 I+<U <$1D '*$ I`#8 8H
5 8X17 HLA-II <"24!`:!8 <5! 05$%1/ 5$ R/ 0<+<U
A%!;#" 0$"*"<4 $! "2,6 0="L)-$ (Th) !5"$ T <"24!G*
BTh 8G+;*5 8D A;4 %"c$$ <"2I$"H!)$"* .;"!408 1+Ö`# 5
www.SID.ir
Archive of SID
EF !"CD B3 A!"#4 B, A!5%
,- !% ,";2K$";856 I;$$ 1;q" 5$ !"T5";*"" <";2'HJ/ 5$
$! 0; %$!'# <";;2';;HJ/ 8;;D '+a";;" &;;*"/ %!$!;;8 ;;;=!%
1;q" 5$ !"T5";* <"2'HJ/ 5$ A%"t)*$ "8$ ;<H08 0$!f1+/
.;*"<8 <";%D A;;<<HI+#;Ñ# 8;1+#2 ';+" ";2K$"856 I$$
|;$!'# B%!$!;8 ;;=!% +- ";# 2- !% 5 ;4"D0#" "2'HJ/
<";2<%";D0;)"6 I+;+e# <$1D .(2j)%!$% A$1#2 8D $! 0%(!8
O1;;P8 1;$5 9$%$1;$$ ';+" %!;;U!8 <";;205! 8;;D 0;)HJ/
:;"!408
(clump)A%!;# %";c$$ !% "2'HJ/ 0e+\/ ]$"## 'G7 8D
VP;* !% <%";D0;)"6 ";$ I+:!D!GT!"!#$$ <%$;e# !!Ñd 5
_+M1# <$1D 0\*"<8 05! ,!+*"<+#!GT6 05! B"2'HJ/
;;X <";2<%"D0)"6 ,"85 N2 !!Ñd .;4"D0#" "2<%"D0)"6
]`;18 ";D $! HPAs ;;X <";2<%";D0;)"6 0*!1D B HLA
";D 0;)HJ/ <";2, 0;)"6 Ç.d ,6 4"\"% 8D .;<H08 8U$!8
1;++Z# 8;D ';+" I+H51;GH 5$ A%"t);*$ "8$ ;4 O1P8 I+H51GH
<$A;;+á+/ 05! MAIP .;;8"c"$0;8 0;)HJ/ 0)+7+" 0)"6
5$ vx!;#e8 8;H '*$ 0)HJ/ ]""/ 5$ A%"t)*$ ;<85"+" 5 '*$
0;<)\8 ç8 Ä$1( 05! .%!408 8+C# <$8%P<8 ,"T;<<H$;2$
1+;7t# !% 8;D1c# 8;D 5"+" '+" '81b <"24!\GT 5$ A%"t)*$ 1D
^$";)" !% 95";t# 8;D 1c<8 %!$!8 I$$ 8+GH .(>@)%!$% ^$")"
I;$$ 5$ 8;H ;"!;40;8 0$";2A"f1$"856 [*!# A;4 0!$'T
!% %!;40;8 8+;=!# vx!#e8 $.: .;<$"#"08 A%"t)*$ "205!
05! 5% 5$ ,";85 N;2 B";2<%";D0;)"6 0;*!1D ";$ 5 I++e#
.%!4 A%"t)*$
!"H BA!"b "$ 5 !!;1H 1;2 !% %!;408 %"C<1+/ I+<a N2
5 9J`;18 ];d !!;q<8 8D 'HJ/ < !:!"!#$$ <"2A51T
1$";* <";2A51;T ";D 5 A;;$%1T ]+`;1# 8/!D18 9JÑe8
.;<4"D y"\#!$ !% "2!!1H "$ |/"<8
'(
.-#,&+#)*
4";d !% 5 ;D"$08 8e*!# '71* 8D 'HJ/ < !:!"!#$$
%!!;8 3> 8;D 0;)HJ/ <";2, 0)"6!;:6 <";2N)7+* 1X"d
I+;<a N;2 5 ";2<!"#+D 0-1D !% "2, 0)"6 I$$ .;"$A;+*!
ñ;d"\8 8;$$!$ 5$ Ç;;2 .;;"!$% K%" ,!- 4"%)"$ Y!$!7
,$;;<#bJ7 !% 0#G7 8+:5$ 8<+85 %"c$$ B'HJ/ < !:!"!#$$
~!% 8;D s#H ,0)HJ/ <"2<%"D0)"6 5 "2, 0)"6 â%!!8 !%
I;$$ 0;*!1D ';CU 9"""`8$ 5$ A%"t)*$ 5 "2,6 K%" 1)1+D
.;4"D08 "2K$"856 ^$")" 1+7t# 5 ]8$!7
0;)HJ/ <";2, 0;)"6 0;*!1D <$1D <%;e)8 <"205!
<";;;2<%";;;D0;;;)"6 5 (PCR-SSP, PCR-RFLP :1;;;+q")
!% (MAIP 5 <1)8!)$";*!G( ,,!+;*"<+#!GT6 1;+q")0;)HJ/
$! %!;- ã"- .$"e8 5 "$$'8 s$ 12 "8$ ;<4"D08 Ä1)*%
.;"!$%
'+;*"7d 'G7 8D 0)HJ/ <"2, 0)"6 0*!1D %!!8 !%
!% 95";;t# B PCR-RFLP 5 PCR-SSP 05! 5% 95";;t)8
0:!;`:!8 05! 5% I$$ "D HPAs0-1D I++e# ^$")" 0!$'T
0)HJ/ <"2, 0)"6 !"1)"$ !% 95"t# .(>j)'*$ A;4 O1P8
';+#2$ 0!$'T !% 1++Z# 8D 1c<8 9G)M8 <"2'+e#U I+D
HPA-1 4"Ö8 <$1D %!408 "+"% 9G)M8 y"%" !% "2,6 0<+:"D
!% ";8$ ';*$ N;C8 0<+:";D 1q" 5$ (0$"/5!$),")*!/;+t* !%
";$ 5 ;;D"$08 <1)#H '+#2$ (!5% :14)0$"+*6 <"2!!1H
';+#2$ 0$"+;*6 <"2!!1H 5$ 0-1D 5 I/$ !% 8H HPA-4
!% ";8$ ("2!!;1H I;$$ !% ,6 b 4"`4$ %!U5 'G7 8D)%!$%
.(>@);4"D08 y!D18"" 5 '+#2$ NH ,")*!/;+t* I+D
8;D J);\8 ,$!"#+D <$1D .*"<8 <"2'HJ/ o"M)"$ <$1D
1;D !";#+D 8H 0$"2, 0)"6 ;b"( <"2'HJ/)0)HJ/ '85"%8
<!"T5";* <";2K$";856 ,('*$ <%"D0)"6 <$!$% "2,6 8+G7
A%"t);*$ .;"!$% $! %!- ã"- A"f$"U (Cross match)]D"%)8
www.SID.ir
Archive of SID
,"f$"4 ,"T38
References :
1- Rinder HM, Tomer A. Platelet production kinetics and
Homostasis. In: Simon TL, Snyder EL, Solhem BG,
Stowelm CP, Straus RG, Potrides M, editors. Rossi's
principles of transfusion medicine. 4th ed. West Sussex,
UK: Weilly-Blackwell; 2009. p. 148-67.
2- Rahgozar S, Pakravan G, Ghaedi K. Cellular adhesions
and signaling pathways in platelets. Sci J Iran Blood
Transfus Organ 2011; 8(1): 60-73.[Article in Farsi]
3- Fisk JM, Pisiotto PT, Syder EL, Perrota PL. Platelet
and related products. In: Hillyer CD, Silbrestein LE,
Ness PM, Anderson KC, JD Robac. Blood banking
and Transfusion Medicine: Basic principles and
practice. 2nd ed. Churchil-Livingston Elsevier; 2007. p.
308-41.
4- Platelet & Transfusion. [booklet 31]. Iranian Blood
Transfusion Organization; 2003.
5- Webert KE, Smith JW, Arnold DM, Chan HHW,
Heddle NM, Keltonj C. Red cell, platelet and white
cell Antigens. In: greer JP, Foester J, Rodgers GM,
Paraskevas F, Glader BE, editors. Wintrobe's Clinical
Hematology. 12th ed. Philadelphia: Lippincott Williams
and Willcins; 2009. p. 631-71.
6- Vandermeer PF, Korte D. The buffy-coat method. In:
Blajchman MJ, Cid J, Lozano M. Blood component
preparation, from benchtop to bedside. 1st ed. Bethesda,
Maryland: American Association of Blood Banks;
2011. p. 55-82.
7- Beshkar P, Pourfathollah AA, Shaiegan M, Akhound
MR. Platelet activation and IL-8 production in platelet
concentrates prepared by buffy coat and PRP method
Sci J Iran Blood Transfus Organ 2007; 4(1): 41-
50.[Article in Farsi]
8- Henry ZY, Chien P, Indik ZK, Schneber AD. Human
platelet FCLRIIA and phagocytes in immune-complex
clearance. Mol Immunol 2011; 48(4): 691-6.
9- Langer HF, Daub K, Braun G, Schonberger T, May
AE, Schalerr M, et al. Platelets recruit human dendritic
cells via Mac-1/JAM-C interaction and modulate
dendritic cell function in vitro. Arterioscler Thromb
Vasc Biol 2007; 27(6): 1463-70.
10- Murphy S. Preparation and storage of platelet products.
In: Simon TL, Dzik WH, Snyder EL, Stowell CP,
6W UDXVV5 * 5 RVVL¶VSULQFLSOHVRI W UDQVIXVLRQ 0 HGLFLQH
3rd ed. Philadelphia: Lippincott Williams & Willcins;
2002. p. 220-31.
11- Aye MT, Palmer DS, Chulivi A, Hashemi S. Effects of
filtration of platelet concentrates on the accummolation
of cytokines and platelet release factors during storage.
Transfusion 1995; 35(2): 117-24.
12- Kaufman RM. Platelets: testing, dosing and the storage
lesion--recent advences. Hematology Am Soc Hematol
Educ Program 2006: 492-6.
13- Rumjantseva V, Hoffmeister KM. Novel and
unexpected clearance mechanisms for cold platelets.
Transfus Apher Sci 2010 ; 42(1): 63-70.
14- Blajman MA. Novel platelet products, substitutes and
alternatives. Transfus Clin Biol 2001; 8(3): 267-71.
15- Mac Farland JC. Platelet and granulocyte antigens and
antibodies. In: Roback JD, Rae Combs M, grossman
BJ, Hillyer CD. Technical manual. 6th ed. Bethesda,
Maryland: American Association of Blood Banks;
()
'(J/ < !:!"!#$$
2008. p. 525-47.
16- Curtis BR, Macfard JC. Platet Immonology and
Alloimmunization. In: Rossi's principles of transfusion
medicine. 4th ed. West Sussex, UK: Weilly-Blackwell;
2009. p. 168-86.
17- Allen DL, Lucas GF, Ovweband WH, Murphy MF.
Platelet and neutrophil antigens. In: Murphy MF,
Pamphilon D. Practical transfusion medicine. 2nd ed.
Massachusetts: Blackwell; 2005. p. 50-60.
18- Cosgrave LJ, Vaughan HA , Tjandra JJ, Thurlow PJ,
Mckenzie IF. HLA(class I) antigens on platelets are
involved in platelet function. Immunol Cell Biol 1988;
66( Pt 1): 69-77.
19- Luming park ET. Approach to the platelet refractory
patient. In: Hillyer DD, Hillyer KL, Storbel FJ,
Jefferies LC, Silberstien LE. Handbook of transfusion
medicine. 3rd ed. California: Academic Press; 2001. p.
209-20.
20- Freedman J, Hornestin A. Simple method for
differentiating between HLA and platelet-specific
antibodies by flow cytometry. Am J Hematol 1991;
38(4): 314-20.
21- Bertland G, Kaplan C. Genotyping applied to platelet
immunology: When? How? Limits. Transfus Clin Boil
2009; 16(2): 164-9.
22- Lucas GF, Metcalfe P. Platelet and granulocyte
glycoprotein polymorphisms. Transfus Med 2000;
10(3): 157-74.
23- Kunicki KJ, Naugent DJ. Human platelet antigens. In:
Hillyer CD, Silbrestein LE, Ness PM, Anderson KC,
JD Robac: Blood banking and Transfusion Medicine:
Basic principles and practice. 2nd ed. Churchil-
Livingston Elsevier; 2007. p. 112-28.
24- Ye F, Kim C, Ginsberg MH. Molecular mechanism of
inside-out integrin regulation. J Thromb Haemost
2011; Suppl 1: 20-5.
25- Ouweband WH, Willington TB. Essential immunology
for transfusion medicine. In: Murphy MF, Pamphilon
D. Practical transfusion medicine. 2nd ed. West Sussex,
UK: Weilly-Blackwell; 2005. p. 13-23.
26- Verdichio-Moraes CF, Toralles-Pereira C, Grotto RM,
Silva GF, Pardini MI. Allelic frequencies of HPA-1 to
5 human platelet antigens in patients infected with
hepatitis C virus. J Am Virol 2009; 81(4): 757-9.
27- Curtis BR. Genotyping for human platelet alloantigen
polymorphisms: applications in the diagnosis of
alloimmune platelet disorders. Semin Thromb Hemost
2008; 34(6): 539-48.
28- Afshar-kharaghan V, Vijyan V, Bray FB. Platelet
polymorphism. In: Michelson AD. Platelet. 2nd ed.
California: Academic Press; 2007. p. 281-308.
29- Koutsogianni PI. Nomenclature of human platelet
antigens and clinical conditions. Haematology 2004; 7
(supp1): 82-8.
30- Kupatawintu P, Nathalang O, O-Charoen R,
Patmasiriwat P. Gene frequencies of the HPA-1 to 6
and Gov human platelet antigens in Thai blood
donors. Immunohematology 2005; 21(1): 5-9.
31- Tinmouth AT, Semple E, Shehata N, Branch DR.
Platelet immunopathology and therapy: a Canadian
Blood Services Research and Development
www.SID.ir
Archive of SID
EF !"CD B3 A!"#4 B, A!5%
Symposium. Transfus Med Rev 2006; 20(4): 294-314.
32- Madani T, Samiee Sh, Attaei Z, Kavari, Mostakhdemin
M, Shaiegan M, et al. Platelet antigens frequency in
blood donors: comparison of molecular detection with
ELISA method ( for HPA-1a ). Sci J Iran Blood
Transfus Organ 2007; 4 (3): 165-74.[Article in Farsi]
33- Ouwehard WH, Stafford P, Gheveart C, Campbell K,
Allen D, Smith G, et al. Platelet immunology, present
and future. ISBT Science Series 2006; 1(1): 96-102.
34- Werbert K, Chan H, Smith JW, Heddle N, Kelton j.
Red cell, platelet and white cell antigens. In: greer JP,
) RVWHUM/ XNHQV-1 5 RGJ HUV* 0 : LQW URE¶V &OLQLFDO
Hematology. 11th ed. Philadelphia: Lippincott Williams
and Willcins; 2004. p. 808-17.
35- Stafford P, Garner SF, Rankin A, Kekomaki R,
Watkins NA, Ouwehand WH. A single-nucleotide
polymorphism in the human ITGB3 gene is associated
with the platelet-specific alloantigen Va (HPA-17bw)
involved in fetal maternal alloimmune
thrombocytopenia. Transfusion 2008; 48(7): 1432-8.
36- Xu X, Zhu F, Ying y, Tao S, Liu Y, Hong X, et al.
Simultaneous genotyping of human platelet antigen-1
to 17w by polymerase chain reaction sequence-based
typing. Vox Sang 2009; 97(4): 330-7.
37- Blood storage effect on Immune system function.
[booklet 57]: Iranian Blood Transfusion Organization;
2003. p. 13-40.
38- Schleuning M, Bock M, Mempel W. Complement
activation during storage of single-donor platelet
concentrates. Vox Sang 1994; 67(2): 144-8.
39- Pourfatollah AA, Shaiegan M, Namiri M, Babae GR.
Effect of gamma irradiation on lymphocyte
proliferation and IL-8 production by lymphocytes
isolated from platelet concentrates. Arch Med Res
2008; 39(6): 590-3.
40- Shaiegan M, Pourfatollah AA, Namiri N, Babaee GR.
Generation of IL-8 and TNF-alpha in platelet
concentrates during storage. Arch Iran Med 2006; 9(1):
61-4.
41- Wadhwa M, Saghatchian MJ, Lubenko A, Contreras
M, Dilger P, Bird C, et al. Cytokine level in platelet.
Concentrates quantitation by bioassays and immune
assays. Br J Haematol 1996; 93: 255-60.
42- Stock G, Berkowicz D. Cytokine production during
blood component storage. In: Davenport RD, Synder
EL. Cytokine in Transfusion Medicine: A Primer.
Bethesda, Maryland: American Association of Blood
Banks; 1997. p. 30-8.
43- Waldhwa M, Krailadsiri P, Dilger P, Gaines Das R,
Seghatchian MJ, Thorpe R. Cytokine levels as
performance indicators for white blood cell reduction
of platelet concentrates. Vox Sang 2002; 83(2): 125-36.
44- Hurd CM, Cavanagh G, Schuh A, Ouwehand WH,
Metcalf P. Genotyping for platelet-specific antigens:
techniques for the detection of single nucleotide
polymorphism. Vox Sang 2002; 83(1): 1-12.
45- Cavanagh G, Dunn AN, Chapman CE, Metcalfe P.
HPA genotyping by PCR sequence-specific priming
(PCR-SSP): a streamlined method for rapid routine
investigations. Transfus Med 1997; 7(1): 41-5.
46- Helmberg W, Folsch B, Wagner T, Lanzer G.
Detection and differentiation of platelet-specific
(*
antibodies by flow cytometry: the bead-mediated
platelet assay. Transfusion 1997; 37(5): 502-6.
47- Worfolk LA, MacPherson BR. The detection of platelet
alloantibodies by flow cytometry. Transfusion 1991;
31(4): 340-4.
48- Navarrete VC. Human leucocyte antingens. In: Murphy
MF, Pamphilon DH. Practical transfusion medicin.
France: Black Well Science; 2001. p. 43-9.
49- Zhou B, SaitoS, Nakazawa Y, Kobayashi N, Matsuda
M, Matsumoto M, et al. Existence of an
immunoglobulin G component of naturally occurring
HLA class I antibodies that are not directed against
self-antigens in human serum. Tissue Antigens 2008;
72(2): 98-104.
50- Fabris F, Scandellari R, Randi ML, Carraro G,
Luzzatto G, Girolami A. Attempt to improve the
diagnosis of immune thrombocytopenia by combined
use of two different platelet autoantibodies assays
(PAIgG and MACE). Haematologica 2002; 87(10):
1046-52.
51- Stockelberg D, Hou M, Jacobsson S, Kutti J, Wedenvik
H. Detection of platelet antibodies in chronic idiopathic
thrombocytopenic purpura (ITP). A comparative study
using flow cytometry, a whole platelet ELISA, and an
antigen capture ELISA. Eur J Hematol 1996; 56(1-2):
72-7.
52- Rozman P. Platelet antigens. The role of human platlet
alloantigens (HPA) in blood transfusion and
transplantation. Transpl Immunol 2002; 10(2-3): 165-
81.
53- Kickler T. Platelet Immunology. In : Anderson Ness.
Scientific Basis of Transfusion Medicine Implications
for Clinical Practice. 2nd ed. Philadelphia: WB
Saunders Company; 2006. p. 227-36.
54- Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni
TG, Muto KN, Holland PV. HLA class II antibodies in
transfusion-related acute lung injury. Transfusion
2001; 41(10): 1244-8.
55- Colman RW, Marder VJ, Clowes AL, George JN,
Goldhaber SZ. Hemostasis and thrombosis: basic
principles and clinical practice. 5th ed. Philadelphia:
Lippincott Williams and Wilkins; 2006. p. 1100.
56- Modified Rapid MAIPA Assay. Available at:
http://www.nibsc.ac.uk/science/diagnostics/transfusion
__transplantation/platelets/resources/modified_rapid_
maipa_protocol.aspx
57- Amiri F. Survey of anti-HLA antibodies by
flowcytometry method in patients with hematological
disorders.[MS Dissertation]. Iran. Tehran. Iranian
Blood Transfusion Organization. 2003. [Persian]
58- Shaiegan M, Amiri F, Derakhti Gonbad MH,
Aghaeipour M, Maghsudlu M, Tabatabaian A, et al.
Flowcytometric evaluation of antibodies against
histocompatibility antigens and platelet-specific
antigens in patients with hematological disorders
following the the transfusion of platelets concentrates.
Sci J Iran Blood Transfus Organ 2005; 1(2): 27-
36.[Article in Farsi]
59- Dohlinger S, Humpe A, Conner J, Kohler M, Legler
TJ. Flow-cytometric screening of platelet antibodies
with previovsly frozen cells. J Immunol methods 2005;
297(1-2): 167-75.
www.SID.ir
Archive of SID
,"f$"4 ,"T38
60- Galel SA, Nguyen DD, Fontaine MJ, Goodnough MT,
Viele MK. Transfusion Medicine. In: Wintrob's clinical
hematology. 12th ed, Philadelphia: Lippincott Williams
and Wilkins; 2009. P. 671-2.
61- Chiras T, Papadakis ED, Katopodi A, Chatzianesti E,
Fourtounas K, Papakonstantinou S, et al. Platelet Gp
IIIA polymorphism HPA-1 (PLA1/2) is associated
with hypertension as the primary cause for end-stage
renal disease in hemodialysis patients from Greece. In
Vivo 2009; 23(1): 177-81.
62- Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman
P, Brenner MK. Clinical bone marrow and blood stem
cell transplantation. 3rd ed. UK: Cambridge University
Press; 2004. p. 115.
63- Leitner GC, Tanzmann A, Stiegler G, Kalhs P, Greinix
HT, Hocher P, et al. Influence of human platelet
antigen match on the success of stem cell
transplantation after myeloblative conditioning. Bone
Marrow Transplant 2003; 32(8): 821-4.
64- Minor Histocompatibility Complex. [booklet 67].
Iranian Blood Transfusion Organization; 2006. p. 1-2.
65- Silva GF, Grotto RM, Verdichio-Moraes CF, Corvino
SM, Ferrasi AC, Silveira LV, et al. Human platelet
antigen genotype is associated with progression of
fibrosis in chronic hepatitis C. J Med Virol 2012;
84(1): 56-60.
66- Atzeni F, Boiardi L, Nicoli D, Farnetti E, Casali B,
Sarzi-Puttini P, et al. PLA1/A2 polymorphism of the
platelet glycoprotein receptors IIIA in Behçet's disease.
Clin Exp Rheumatol 2011; 29(4 Suppl 67): S38-43.
67- Platelet and granulocyte antigens and antibodies. In:
Brechers ME, Leger RM, Lenden JV, Roseff SD, Rae
("
'(J/ < !:!"!#$$
Combs M, Denomme G, et al. Technical manual. 15th
ed. Bethesda, Maryland: American Association of
Blood Banks; 2005. P. 361-406.
68- Kuhne T. Immune thrombocytopenia(ITP). 1st ed.
Boston: International Medical publishing; 2010. p. 38-
58
69- Elebute M, Stanworth S, Navarete C. Platelet and
granulocyte, transfusion. In: Contreras M. ABC of
transfusion. 4th ed, CA: Weilly-Blackwell; 2008. p. 22-
6.
70- Ehmann WC, Dancis A, Ferziger R, Karpatkin S.
Posttransfusion purpura: conversion of PLA1-negative
platelets to the PLA1-positive phenotype by stored
plasma is not due to the presence of soluble PLA1
antigen. Proc Soc Exp Biol Med 1990 ; 195(2): 192-6.
71- Thibaut J, Merieux Y, Rigal D, Gillet G. A novel assay
for the detection of anti-human platelet antigen
antibodies (HPA-1a) based on the peptide aptamer
technology. Haematologica 2011; DOI:
10.3324/haematol.2011.051276.
72- Allen DL, Abrahamsson S, Murphy MF, Roberts DJ.
Human platelet antigen 1a epitopes are dependent on
the cation-regulated conformation of integrin
6(IIb)!(3) (GPIIb/IIIa). J Immunol Methods 2012;
375(1-2): 166-75.
73- Shaiegan M, Samiei SH, Ataee Z, Madani T, Ahmadi
J, Azarkeivan A, et al. Frequency of Human Platelet
Antigens ( HPA-2,3,5) polymorphism in Iranians
evaluated by RFLP- PCR. IJBC 2011; 3: 101-5.
74- K Takahashi. The Importance of the Workshop of the
Asian Platelet Immunology Working Party (APIWP).
ISBT Science Series 2011; 6(2): 337-8.
www.SID.ir
Archive of SID

EF
Sci!"CD B3 A!"#4
J Iran B, A!5%
Blood Transfus Organ 2012; 9(1):72-93

Review Article

Platelet Immunology

Shaiegan M.1

1
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran,
Iran

Abstract
Background and Objectives
The study of different antigens on platelets which can produce antibodies, reactions between
these antigens and antibodies which are able to induce different situations and diseases, and
different tests to diagnose and manage such situations and diseases are important topics of
platelet immunology. Knowledge about platelet antigens and antibodies that helps their roles in
different diseases to be realised and further information about different tests for such disorders
to be diagnosed and traced are useful.
The present article introduces different topics about platelet immunology using 74 references.
Platelet alloantigens included alloantigens shared with other cells (e.g: human leukocyte
antigen (HLA) system and ABH system), and alloantigens that are assumed to be specific for
platelets (e.g: human platelet antigen (HPA) system). Alloantibodies developed against any of
these antigens through exposure by pregnancy, transfusion, or rarely transplantation are
responsible for different diseases and transfusion reactions like alloimmune thrombocytopenic
syndromes, neonatal alloimmune thrombocytopenia (NAIT), post transfusion purpura (PTP),
platelet transfusion refractoriness (PTR), passive alloimmune thrombocytopenia, and
transplant-associated thrombocytopenia.
To know how to detect these factors and interpret the results helps in using the right test to the
right patient in right time to make a better diagnosis and treatment.

Key words: Platelet Antigen , Platelet Antibody, Blood Transfusion

Received: 20 Oct 2011

Accepted:25 Jan 2012

Correspondence: Shaiegan M., PhD of Immunology. Blood Transfusion Research Center, High Institute for
Research and Education in Transfusion Medicine
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052194; Fax: (+9821) 88601599
E-mail: M.Shaiegan@ibto.ir

(#
www.SID.ir